STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy

Ping-Lian Yang 1,2, Lu-Xin Liu 1,3, En-Min Li 1,3,* and Li-Yan Xu 1,2,*

1 The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China; yang_pinglian@grmh-gdl.cn (P.-L.Y.); 18lxliu2@stu.edu.cn (L.-X.L.)
2 Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China
3 Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, Guangdong, China
* Correspondence: nmli@stu.edu.cn (E.-M.L.); lyxu@stu.edu.cn (L.-Y.X.); Tel: +86-754-88900460 (L.-Y.X.); Fax: +86-754-88900847 (L.-Y.X.)

Received: 26 July 2020; Accepted: 27 August 2020; Published: 30 August 2020

Simple Summary: STAT3, an oncogene, contributes to insensitivity of chemotherapy and radiotherapy in tumor, reduces the clinical efficacy. Meanwhile, STAT3β, a STAT3 splicing isoform, is related to the inhibition of tumor growth and chemosensitivity. STAT3 may become a potential target to overcome the chemo(radio)resistance, which benefit for developing novel drugs targeting STAT3 or alternative splicing regulators.

Abstract: Chemoradiotherapy is one of the most effective and extensively used strategies for cancer treatment. Signal transducer and activator of transcription 3 (STAT3) regulates vital biological processes, such as cell proliferation and cell growth. It is constitutively activated in various cancers and limits the application of chemoradiotherapy. Accumulating evidence suggests that STAT3 regulates resistance to chemotherapy and radiotherapy and thereby impairs therapeutic efficacy by mediating its feedback loop and several target genes. The alternative splicing product STAT3β is often identified as a dominant-negative regulator, but it enhances sensitivity to chemotherapy and offers a new and challenging approach to reverse therapeutic resistance. We focus here on exploring the role of STAT3 in resistance to receptor tyrosine kinase (RTK) inhibitors and radiotherapy, outlining the potential of targeting STAT3 to overcome chemo(radio)resistance for improving clinical outcomes, and evaluating the importance of STAT3β as a potential therapeutic approach to overcome chemo(radio)resistance. In this review, we discuss some new insights into the effect of STAT3 and its subtype STAT3β on chemoradiotherapy sensitivity, and we explore how these insights influence clinical treatment and drug development for cancer.

Keywords: chemoresistance; radioresistance; STAT3; STAT3β; target therapy

1. Introduction

Chemoradiotherapy is the main treatment for various solid malignancies through the induction of tumor DNA damage, and it can be used alone or in combination with surgery. Because of the genetic and epigenetic heterogeneity of cancer, the response to chemoradiotherapy is variable, and accompanied by therapeutic toxicities and resistances that limit the effectiveness of chemoradiotherapy [1–4]. In recent years, many reports have demonstrated that STAT3 contributes to resistance to chemotherapy and radiotherapy [5–7].

Signal transducer and activator of transcription (STAT) proteins are a family of cytoplasmic transcription factors and were discovered by James E. Darnell while investigating interferon signal
transduction [8]. Seven mammalian members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) contribute to multiple biological functions, including cell differentiation, development, proliferation, apoptosis and inflammation [9]. STAT3 shares a common structure with other STAT proteins, and consists of an amino-terminal domain (NTD) that is required for cooperative DNA binding [10], a coiled-coil domain (CCD) for STAT3 recruitment to a receptor, a DNA-binding domain (DBD), a linker domain, an Src homology 2 (SH2) domain, which is involved in STAT3 dimerization, and a C-terminal transcriptional activation domain (TAD) for transcription activation (Figure 1) [11,12].

![Diagram of the structure and alternative splicing pattern of STAT3](image)

**Figure 1.** Schematic diagram of the structure and the alternative splicing pattern of STAT3. PCBP1 binds to “UCCCCCCCG” and promotes the usage of an alternative 3' splicing site in exon 23, which increases the expression of STAT3β. The TAD (transcriptional activation domain) of STAT3α is replaced by FIDAVWK.  

STAT3 is identified as an acute-phase response factor that is activated in response to IL-6, growth factors and hormones [13–17]. Once STAT3 Tyr705 is phosphorylated by receptor tyrosine kinases (JAK) or non-receptor tyrosine kinases (Src, Abl), STAT3 homodimerizes or heterodimerizes through its SH2 domain; it then translocates into the nucleus and binds to its recognition GAS (TTCN2-GAA) elements in target genes to modulate gene transcription [18,19]. STAT3β is an alternatively spliced variant, in which the 55 C-terminal amino acid residues of STAT3α, including serine 727, are replaced by seven amino acid residues (FIDAVWK). Poly-C binding protein-1 (PCBP1) can interact with an exonic splicing suppressor in STAT3 exon 23 by binding to the sequence “UCCCCCCCG”, and can then regulate the proportion of STAT3α/STAT3β (Figure 1) [20]. STAT3β is generally considered a dominant-negative regulator of STAT3α. However, it still acts as a significant transcriptional regulator for its own specific genes [21]. Constitutively-activated STAT3 has been frequently detected in human cancers and contributes to cancer progression [22–30]. STAT3 activation is also associated with maintaining embryonic stem cell self-renewal. While STAT3 deficiency causes early embryonic lethality, STAT3β itself can rescue the embryonic lethality [31–33].

Herein, this review focuses on the mechanism of STAT3 in resistance to chemo(radio)therapy and improvement in the therapeutic effect of chemoradiotherapy (CRT)-resistant tumors by targeting STAT3.

2. Feedback Loop Leading to STAT3 Activation

Mammalian cells use various regulatory mechanisms, involving feedback loops and crosstalk between signaling pathways, to adjust to perturbations in cellular homeostasis [34]. These mechanisms
are pivotal in determining cell fate under dynamic physiological circumstances and pose a barrier to the effective therapy of cancer. The development of small-molecule inhibitors has significantly improved progression-free survival against receptor tyrosine kinases (RTKs), but disappointing outcomes remain due to the emergence of drug resistance (Figure 2). Interestingly, erlotinib, as an RTK inhibitor, increases STAT3 phosphorylation (Tyr705) in EGFR-mutant ono-small-cell lung cancer (NSCLC) cells through an autocrine loop, whereas knockdown of STAT3 decreases erlotinib-resistant colony numbers in the presence of erlotinib. This suggests that the interruption of a STAT3 feedback loop blocks chemotherapy resistance [35]. A similar result was reported for HER2-overexpressing breast and gastric cancers, where hyperactivated STAT3 signaling-mediated trastuzumab resistance occurred via a feedback loop comprising FN/EGF/IL-6 upstream mediators [36]. Moreover, MEK inhibitor induced STAT3 feedback activation, leading to resistance in KRAS mutant lung cancer cells [37]. MEK blockage has poor clinical outcome in KRAS-mutant (KRASMT) colorectal cancer cells, and siRNA-mediated knockdown of macrophage inhibitory factor (MIF) restored sensitivity to refametinib by decreasing STAT3 phosphorylation [38]. In addition, combined STAT3 and BCR-ABL1 inhibition can attenuate BCR-ABL1 kinase-dependent TKI resistance in chronic myeloid leukemia; additionally, combined with MEK inhibitors AZD6244, PD98059 and trametinib in KRASMT pancreatic and colon cancer cells, it increases the suppression of tumor growth [39,40]. These results confirm the cross-talk between STAT3 signaling and RTKs. Some phenomena suggest that STAT3 is activated through cross talk between RTKs. Upon MEK inhibitor treatment, c-MET, but not IL-6, upregulates phosphorylation of STAT3. The combination of JAK1/2 and c-MET inhibitors increased the effect of MEK inhibition in KRASMT xenograft models [41]. In addition, EGFR and IL-6 signaling could in turn activate STAT3 after treatment with erlotinib [35]. Clearly, a combination of STAT3 pathway inhibitors and RTKs may offer a promising strategy to improve chemotherapeutic efficacy.

Drug-sensitive, oncogene-addicted cancer cells secrete factors that contribute to drug resistance via feedback mechanisms. For example, the secretion of IL-6 in turn stimulates the STAT3 pathway and mediates resistance to PI3K inhibitors [42]. IL-11, a member of the IL-6 family, is upregulated in cisplatin-stimulated cancer-associated fibroblasts, and then IL-11 activates the STAT3 signaling pathway, leading to lung adenocarcinoma cell resistance to cisplatin [43]. DeClerck and colleagues revealed the relationship between environment-mediated drug resistance (EMDR) and STAT3. In the presence of soluble IL-6 receptor (sIL-6R), IL-6 effectively activated STAT3 in neuroblastoma and prevented drug-induced apoptosis in neuroblastoma in a STAT3-dependent manner. Furthermore, monocytes, non-myeloid cells and Treg cells were part of the reciprocal loop of STAT3 activation [44]. IL-6 can be involved in regulating leukemic stem cell chemoresistance in acute myeloid leukemia (AML) via osteopontin (OPN) autocrine/paracrine signaling. AML cell proliferation and apoptotic inhibition were mediated through the AKT/VEGF/STAT3/CXCR4/IL-6 loop under three-drug (daunorubicin, cytarabine and idarubicin) treatment [45]. Another cytokine, IL-10, causes STAT3 phosphorylation to decrease the sensitivity of B16 melanoma cells to chemotherapeutic agents through an autocrine loop [46]. IL-10RA upregulation drives the resistance to crizotinib in anaplastic large cell lymphoma (ALCL) through an autocrine positive feedback loop. The IL-10/IL-10RA signaling pathway can reverse the effects of crizotinib-inhibition on STAT3 activity. Activated STAT3 further binds to the transcriptional start sites of IL-10/IL-10RA/IL-10RB in ALCL cells [47]. Trastuzumab treatment rendered resistance to itself, facilitated epithelial-to-mesenchymal transition and enhanced metastatic potential in gastric cancer cells through an IL6/STAT3/Jagged-1/Notch positive feedback loop [48]. MicroRNAs that regulate STAT3 activation are additional molecular mediators that contribute towards chemotherapeutic resistance and tumorigenicity. The IL-6R/STAT3/miR-34a feedback loop was required for maintenance of the mesenchymal phenotype and promoted invasion and metastasis in colorectal cancer [49]. Similarly, an IL6R/STAT3/miR-204 feedback loop was correlated with the cisplatin resistance of epithelial ovarian cancer cells [50]. These reports indicate that miRNA-dependent regulation of the STAT3 axis could provide a chance to overcoming the chemoresistance of cancer patients.
In addition, STAT3 on Tyr705 correlates with Burkitt lymphoma (BL) chemoresistance. Zhong’s group revealed that STAT3 confers chemoresistance to cells by mediating the antioxidant feedback [51]. In response to reactive oxygen species (ROS) after chemotherapy, STAT3 is phosphorylated and increases the expression of glutathione peroxidase (GPx1) and superoxide dismutase 2 (SOD2), thus reducing the level of ROS. The reduction of ROS is related to multidrug (CODOX, cyclophosphamide, vincristine and doxorubicin) resistance in BL cells [51].

![Figure 2. Schematic representation of different ratios of STAT3α/STAT3β and their functions in therapy sensitivity.](image)

**Figure 2.** Schematic representation of different ratios of STAT3α/STAT3β and their functions in therapy sensitivity. (a) The STAT3 signaling pathway confers therapy resistance to cells, mainly by mediating its target genes for cell survival, proliferation and inhibition of apoptosis. It promotes epithelial-mesenchymal transition, restores cancer stem cell properties, enhances DNA repair and attenuates ROS levels. RTK inhibitors can augment cell survival and proliferation via feedback activation of STAT3. Thus, in combination with RTK inhibitors, STAT3 inhibitors can be an effective strategy for therapy resistance. (b) STAT3β activation is better for cell growth inhibition and apoptosis, in contrast with STAT3α functions. Switch regulation for STAT3α to STAT3β is a challenging approach for resensitization to chemotherapy. In the context of a high expression level of STAT3β, RTK inhibitors that activate STAT3β via a feedback loop may be of benefit for cell apoptosis. Abbreviations: AKT, protein kinase B; CSCs, cancer stem cells; EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; JAK, Janus kinase; P, phosphorylation; PCBP1, poly-C binding protein-1; ROS, reactive oxygen species; RTKi, receptor tyrosine kinase inhibitor; RTKs, receptor tyrosine kinases; STAT3, signal transducer and activator of transcription 3.

3. **STAT3 Activation by Radiation**

Radiotherapy, alone or in combination with surgery and chemotherapy, is an indispensable link in comprehensive cancer treatment. Radiotherapy causes DNA damage directly or indirectly through generation of ROS and induces various forms of cancer cell death, including apoptosis, autophagy, mitotic catastrophe, necrosis and senescence. Radiosensitivity of tumor cells is one of the main biological factors that affect clinical outcomes [52–55]. Accumulating evidence indicates a link between STAT3 and radiosensitivity [56–60]. STAT3 Y705 activation occurs in a dose- and time-dependent manner upon radiation, mediates hepatobiliary malignancies and maintains stem cell self-renewal and tumorigenic potential [61–65]. STAT3 correlates with resistance to radiotherapy in HER2-positive breast cancer tissue, and radiation resistance in breast cancer stem cells is strongly associated with a high expression of STAT3 [66,67]. Potential STAT3 inhibitors can decrease the production of ROS and down-regulate phosphorylation of STAT3 and Bcl-2, restoring sensitivity to radiation, which offers
an effective approach for treating triple-negative breast cancer cells [68]. Treg cells can regulate resistance to radiation in head and neck cancer. STAT3 antisense oligonucleotide (ASO) inhibited the phosphorylation of STAT3. ASO, in combination with radiation, decreased the population of M2 macrophages, Treg cells and myeloid-derived suppressor cells and resulted in potential antitumor immune responses [69]. Constitutive phosphorylation of STAT3 Tyr705 is present in B-1 lymphocytes and contributes to radioresistance. The microenvironment of the peritoneal cavity is important for B-1 cell radiation-induced apoptosis (RlA) with high levels of IL-6Rα and IL-10RI. These cytokines are a requirement for B-1 cell radioresistance via activation of STAT3 [56,70]. STAT3 Ser727 phosphorylation is also associated with radioresistance and has been reported to correlate with shortened overall survival and progression-free survival of GBM (glioblastoma) patients [71,72]. Table 1 lists the correlation between STAT3 and chemo(radio)sensitization through the modulation of the STAT3 pathway [59,67,68,73–81].

The development of radioresistance following radiation therapy coincides with the radiation-induced appearance of pSTAT3, epithelial–mesenchymal transition (EMT) and self-renewal. IL6/STAT3/TWIST signaling pathway activation mediates esophageal squamous carcinoma EMT, whereas inactivation of STAT3 by an IL-6 inhibitor or siRNA-mediated downregulation of Twist enhances cancer cell apoptosis and reverses radiation-induced EMT [80]. The STAT3/Slug axis is also connected to EMT phenotypes and cancer stemness that contribute to radioresistance in glioblastoma [82]. Upregulating ALDH1 expression can also induce EMT-associated CSC-like properties and lead to radioresistance via STAT3 activation [83]. Park and colleagues identified signaling as a mechanism for CRC (colorectal cancer) stem cell persistence and radioresistance [78]. Lip-FLLL32 sensitized pancreatic CSCs to chemotherapy and radiotherapy both in vitro and in vivo [7]. ROS have been demonstrated in IR-induced EMT. Some reports describe higher levels of phospho-STAT3 and lower levels of ROS than those in radiosensitive cancer cells [68,84]. Radiation also leads to DNA damage. Several studies report that STAT3 signaling pathway activation is involved in DNA repair. For example, high expression of MRE11, a core protein of the MRN (MRE11/RAD50/NBS1) repair complex, enhances breast cancer cell proliferation and invasion and promotes DNA repair through STAT3 [85]. DNA repair-associated molecules, such as ATM, ATR and BRCA1/2, are upregulated via IL-6/STAT3 signaling in radiation-resistant prostate cancer [86].

Together, these findings provide convincing evidence that STAT3 is activated by radiation and contributes to the cancer phenotype. Both STAT3 Y705 and S727 are potential targets for overcoming clinical radioresistance. Interrupting the STAT3 pathway by using STAT3 inhibitors, RNA interference and short hairpin RNA could sensitize radioresistant cancer cells and improve clinical outcomes.
Table 1. STAT3 contributes to chemo(radio)resistance in various carcinoma types.

| Cancers                        | Cell Lines    | Treatment | Inhibition of STAT3 Activation via Different Methods | In Vitro or In Vivo | Effects                                                                 | Reference |
|--------------------------------|---------------|-----------|------------------------------------------------------|---------------------|------------------------------------------------------------------------|-----------|
| Acute myeloid leukemia         | KG-1/U937     | DNR/Ara-C/IDR | Simvastatin/OPN siRNA                                 | in vitro            | Significantly decreases the viability of cells and the expression level of STAT3, which sensitizes cells to chemotherapy. | [45]      |
| Anaplastic large cell lymphoma  | SUP-M2        | crizotinib | Stattic                                              | in vitro            | Inhibition of STAT3 can reverse the resistance to crizotinib in IR10RA-overexpressed cells. | [47]      |
| B-1 lymphoma                   | B-1 cells     | RT        | STAT3−/− mice                                       | in vitro and in vivo| In STAT3−/− mice, B cells are more susceptible to radiation-induced apoptosis. | [56]      |
| Lung cancer                    | A549/H358/H157| RT        | Niclosamide                                         | in vitro and in vivo| Blocks IR-induced activation of the STAT3/Bcl-2/Bcl-xL pathway and enhances apoptosis. | [59]      |
|                               | A549           | RT        | AZD0530                                             | in vitro            | Inhibits cell migration by blocking Src and enhances sensitivity to IR. | [73]      |
|                               | A549           | RT/cisplatin | shRNA                                               | in vitro and in vivo| Enhances radiosensitivity both in vitro and in vivo and enhances chemosensitivity in vitro. | [74,81]  |
|                               | HCC2429       | RT        | TG101209                                            | in vitro and in vivo| Inhibits STAT3 activation and survivin expression, induces apoptosis and decreases proliferation. | [75]      |
|                               | PC-9           | Erlotinib | STAT3 siRNA/STAT3 shRNA                              | in vitro and in vivo| Inhibition of STAT3 feedback sensitized lung adenocarcinoma to MEK inhibition. | [35]      |
| Breast cancer                  | MCF-7          | RT        | Xanthohumol                                          | in vitro            | Suppresses MDR1, EGFR and STAT3 expression, while increasing death receptor (DR)-4 and DR5 expression, and restores sensitivity to IR and doxorubicin. | [77]      |
|                               | MDA-MB-231/MDA-MB-468 | RT            | Niclosamide/STAT3 shRNA                              | in vitro and in vivo| Niclosamide inhibits STAT3 and Bcl-2 and increases ROS generation in vitro and in vivo; it is identified as a radiosensitizer. shRNA of STAT3 sensitizes breast cells to IR. | [68]      |
|                               | SKBR3          | RT        | Lapatinib/S3I-201                                    | in vitro and in vivo| Inhibition of the HER2-STAT3-survivin axis increases sensitivity in SKBR3 cells. | [67]      |
|                               | BT474          | Trastuzumab | S3I-201                                             | in vitro and in vivo| STAT3 inhibition significantly inhibits tumor growth and sensitizes breast cancer cells to trastuzumab. | [36]      |
| Colorectal cancer              | HCT116/LoVo    | RT        | JAK2 shRNA                                          | in vitro and in vivo| Downregulation of JAK2/STAT3/CCND2 signaling to sensitize cells to radiotherapy and impair cancer stemness. | [78]      |
|                               | HCT116/HCT29   | 5-FU/RT   | Selumetinib                                         | in vitro and in vivo| Increases mitotic catastrophe and apoptosis and decreases STAT3 activation and survivin expression; it also enhances sensitivity to radiotherapy in vivo. | [79]      |
|                               | HCT116         | Refametinib | 4-IPP                                               | in vitro            | Inhibition of 4-IPP sensitizes cancer cells to refametinib. | [38]      |
Table 1. Cont.

| Cancers                  | Cell Lines                  | Treatment | Inhibition of STAT3 Activation via Different Methods | In Vitro or In Vivo | Effects                                                                                                                                                                                                 | Reference |
|--------------------------|-----------------------------|-----------|-----------------------------------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Esophageal carcinoma     | ECa109                      | RT        | AG490                                               | in vitro            | Reverses the IR-induced EMT phenotypes and gene expression via regulation of the IL-6/STAT3/Twist signaling pathway. Attenuates radioresistance under AG490 treatment.                                            | [80]      |
|                          | ECa109/TE13/KYSE150         | RT        | Stattic                                            | in vitro and in vivo| Stattic inhibits STAT3 activation, downregulates HIF-1α and VEGF expression; and confers radiosensitivity in vitro and in vivo.                                                                         | [87]      |
|                          | ECa109/TE13                 | RT        | NSC74859                                           | in vitro and in vivo| Sensitizes cells to radiotherapy in vitro and in vivo via inhibiting STAT3 activation and downregulation of HIF-1α and VEGF expression.                                                             | [88]      |
| Glioblastoma             | D456 GSCs                   | RT        | Ibrutinib                                          | in vitro            | Combines with radiotherapy to disrupt tumor growth and mainly disrupts glioma stem cells by inhibiting bone marrow and X-linked (BMX)/STAT3 activation.                                                   | [64]      |
|                          | GBM-R212                    | RT        | STAT3 shRNA                                        | in vitro            | Reduces STAT3, decrease Slug expression and suppresses cell invasion; inhibits cancer stem cell properties and enhances radiotherapy.                                                                      | [82]      |
|                          | GSC-2/GSC-11                | RT        | Stattic/WP1066                                     | in vitro            | Enhances radiosensitivity of GSC lines by inhibition of STAT3 activation, mainly impacting pSTAT3 on Serine727.                                                                                       | [72]      |
|                          | U251/U87                    | RT        | Cryptotanshinone/WP1066/SH-201                     | in vitro and in vivo| Re-sensitizes radiosensitive cells to radiotherapy by inhibition of STAT3; when combined with ERK1/2 inhibitors, it remarkably eliminates resistant cells and inhibits tumor regrowth. | [89]      |
| Head and neck carcinoma  | UMSCC-17B                   | RT        | Stattic                                            | in vitro and in vivo| Reduces STAT3-mediated HIF-1α expression in response to Stattic.                                                                                                                                     | [90]      |
|                          | UMSCC-22A/UMSCC-22B         | RT        | Linifanib                                          | in vitro            | Cell growth inhibition, G2/M cell cycle arrest and induction of cell death via apoptosis; it overcomes radioresistance by reducing pSTAT3 and expression of its target genes, e.g., cyclin D1, survivin. | [91]      |
|                          | HNSCC-CD44(+)ALDH1(+) cell  | RT        | Cucurbitacin I                                     | in vitro and in vivo| Combines with radiotherapy to suppress tumorigenesis and metastasis and also reduces CSC-like cells.                                                                                                | [76]      |
| Hepatoblastoma           | HepG2.2.15                  | RT        | STAT3D                                             |                     | Suppresses RT-induced hepatitis B virus DNA replication and impairs hepatobiliary malignancies.                                                                                            | [62]      |
|                          | PLC5/Huh-7/Sk-Hep1/Hep3B   | RT        | Sorafenib/STAT3 siRNA                              | In vitro and in vivo| Enhances radiation-induced apoptosis by inhibiting STAT3; it also downregulates Mcl-1, cyclin D1 and survivin expression, overcomes resistance to radiation in cells and suppresses tumor growth in vivo. | [92]      |

5-FU, 5-fluorouracil; Ara-C, cytarabine; Bel-xxL, B-cell lymphoma-extra large; DNR, daunorubicin; DR, death receptor; HIF-1α, hypoxia-inducible factor 1α; IDR, idarubicin; IR, irradiation; MDR1, multi-drug resistance 1; OPN, osteopontin; RT, radiation therapy; siRNA, small interfering RNA; shRNA, short hairpin RNA; STAT3D, dominant-negative mutant STAT3.
4. STAT3 Target Genes Impact Chemoresistance and Radioresistance

Activated STAT3 binds to DNA sequences (GAS element) in target genes and usually correlates with the enhanced expression of anti-apoptotic proteins, prevention of cell cycle arrest and promotion of cell proliferation [21]. A number of target genes, including Bcl-2 [68], Bcl-xL [5], Slug [82], Snail [93], survivin [94] and cyclin D1 [95], which have STAT3 binding sites in their promoters, regulate chemoresistance and radioresistance in a variety of cancer cells. Our group demonstrated that blocking the transcriptional activity of STAT3 by STAT3 isoform STAT3α by STAT3 isoform STAT3β sensitized esophageal squamous cell carcinoma (ESCC) cells to chemotherapeutic agents, namely, cisplatin and 5-FU both in vitro and in vivo [96]. The role of STAT3 target genes in chemo- and radioresistance is discussed in the following section.

4.1. Bcl-2 Family

Bcl-2, Bcl-xL and Mcl-1 are anti-apoptotic members of the Bcl-2 family and frequently dysregulated in various cancers. STAT3 has been shown to significantly enhance Bcl-2 and Bcl-xL promoter activity. Chromatin immunoprecipitation analysis indicates that activated STAT3 directly binds to the promoters of Bcl-2, Bcl-xL and Mcl-1 genes [97,98]. Hajime et al. further revealed the site of STAT3 that directly binds to the putative consensus sequences (position -92/-83) in the Mcl-1 promoter [99]. Thus, aberrant activation of STAT3 can activate Bcl-2 family proteins in various cancer cells [100]. Yu and colleagues suggested that STAT3 upregulated the expression of various target genes (Bcl-2, cyclin D1, c-myc) through a miR-197/CKS1B/STAT3 axis, which conferred chemoresistance to non-small-cell lung cancer [101]. Activated STAT3 increases RANTES (regulated upon activation, normal T cell expressed and secreted factor) and anti-apoptotic Bcl-2 and Bcl-xL expression levels that contributes to tamoxifen-resistance in breast cancer [97,100,102,103]. For cisplatin-induced mitochondrial-related apoptosis, knockdown of STAT3, by using siRNA, attenuated the expression of anti-apoptotic proteins Bcl-xL and Bcl-2 and increased the release of cytochrome C and the expression of Bax [102]. A similar result was found in ovarian cancer cells after treatment with the conditioned medium of cancer-associated fibroblasts [104]. In cisplatin-resistant ovarian cancer cells, NCX-4016 (nitro derivative of aspirin) treatment significantly decreases the protein levels of Bcl-2 and Bcl-xL and induces apoptosis in a time-dependent manner. The study further showed that the downregulation of STAT3 signaling could also inhibit tumor growth both in vitro and in vivo [103]. Doxorubicin-resistant chronic myeloid leukemia cells enhanced phosphorylation of STAT3 and dampened the tumor growth inhibition of TNF-α. STAT3 dephosphorylation can sensitize doxorubicin-resistant Dalton lymphoma to dendritic cell (DC)-derived TNF-α through the downregulation of Bcl-2 upon cucurbitacin I (STAT3 inhibitor) treatment in DC (chronic myeloid leukemia) patients [105]. (-)-Gossypol mainly disrupts Bcl-xL heterodimerization with Bax and Bad and overcomes the protection of prostate cancer cells by Bcl-xL. It also enhances the chemotherapy of docetaxel in inhibiting tumor growth and inducing apoptosis both in PC-3 cells and in xenograft model of prostate cancer [106].

The STAT3/Mcl-1 signaling axis is a target for overcoming resistance to BH3 mimic ATB-737 (Bcl-2 inhibitor). Sorafenib, a multiple tyrosine kinase inhibitor, has been found to target Mcl-1 and synergize with ATB-737 to induce apoptosis in glioma cells [107]. However, (-)-gossypol also increases the expression levels of Mcl-1 [106], which may result in drug resistance. Sorafenib sensitizes prostate cancer cells to (-)-gossypol through the attenuation of Mcl-1 expression in vitro and in vivo. Using siRNA to downregulate Mcl-1, Lian et al.’s study also verified that prostate cancer cells were sensitized to (-)-gossypol [108].

Exposure of cells to IR (irradiation) can also increase Bcl-2 expression levels, which are associated with radioresistance [109]. In another study, radiotherapy resulted in the activation of STAT3 and Bcl-2 in triple-negative breast cancer. Persistent activation of STAT3 and Bcl-2 contributes to radioresistance [68]. Moreover, radioresistance was observed in DAB2 interactive protein-deficient prostate cells due to DNA double-strand break repair and the evasion of apoptosis with significantly higher levels of Bcl-2 and STAT3 [110]. Radiation induces the activation of STAT3 and increases the levels of Bcl-2/Bcl-xL.
in human lung cancer cells. Treatment with niclosamide can sensitize radioresistant lung cancer cells to ionizing radiation [59]. STAT3 and Mcl-1 are also induced by irradiation and are involved in the radioresistance of ESCC cells. A study further suggested that Mcl-1 inhibition was involved in the induction of apoptosis and the enhancement of DNA damage through SOCS1 overexpression [5]. Taking these results together, the upregulation of the Bcl-2 family proteins is the inescapable causative factor of chemo- and radioresistance.

4.2. EMT Regulators

Indeed, STAT3 is also important for initiating the epithelial-mesenchymal transition (EMT) program, which is associated with cancer therapy resistance [111]. Snail, Slug and Twist proteins are involved in regulating EMT [112]. Reports have shown that STAT3 can directly bind to the Slug promoters in a chromatin immunoprecipitation assay [82]. It also binds to Snail [93] and Twist1 [113] promoter and enhances their promoter activity. Reports have shown that STAT3/Slug was associated with GBM recurrence. STAT3 enhancement of tumor motility and EMT-like characteristics in GBM cells correlated with Slug expression. The efficacy of radiotherapy can be improved in vitro and in vivo by blocking STAT3/Slug signaling. Moreover, the blockage of STAT3/Slug also improves survival in GBM-R2I2 xenografts [82]. Slug was also upregulated in ovarian cancer and conferred chemoresistance to cells through the activation of STAT3 and the cross talk between p53/RAS signaling [114]. In other study, ovatodiolide (Ova), a diterpenoid isolate of Anisomeles indica, could overcome resistance to temozolomide (an alkylating agent) in glioblastoma. It reduced Slug, Vimentin, N-cadherin and β-catenin and also disrupted STAT3 signaling [115]. Moreover, Ova can significantly inhibit nasopharyngeal cancer cell tumor growth and enhance sensitivity to cisplatin in vivo. The study also found that Ova reduced Slug expression and inhibited EMT via abrogation of STAT3 signaling [116].

STAT3 upregulates the expression of Snail, contributes to temozolomide resistance in GBM and is associated with recurrent GBM tumors [117]. Another report also showed Snail/Slug-mediated chemoresistance to cisplatin in ovarian cancer cells [114]. Radioresistant head and neck squamous cell carcinoma cells showed high expression of Snail and Twist as the activation of STAT3 levels increased [76]. Increased expression of Snail was correlated with a poor prognosis in CRC patients. CRC cells that overexpressed Snail were also found to be more resistant to 5-FU [118]. Rectal cancer cells were resistant to ionizing radiation and 5-FU treatment due to the activation of STAT3 and the TGF-β/Smad signaling pathway. Treatment with metformin increased the sensitivity of rectal cancer cells by increasing apoptotic cell death as well as by downregulating Snail and Twist [119].

Twist basic helix loop helix transcription factor 1 (Twist1), a regulator of EMT, is upregulated in cisplatin-resistant ovarian cancer cells via STAT3 activation [120]. Inhibition of the IL6/STAT3/Twist signaling pathway could be a useful strategy to reverse radiation-induced EMT and radioresistance in ESCC [80]. Moreover, the inhibition of STAT3 activity and Twist1 transcription could suppress EMT and inhibit tumor progression and chemoresistance in ovarian cancer and renal cancer cells [113]. Wu et al. reported that DAB2 interactive protein suppressed the expression of Twist1 and the activation of STAT3. The report also demonstrated that Twist1 and STAT3 were crucial for the pirarubicin chemoresistance and tumor recurrence in non-muscle invasion bladder cancer, and this result could be reversed via DAB2 interactive protein [121].

4.3. Survivin

Survivin is an inhibitor of the apoptosis protein family, and its aberrant expression correlates with a poor prognosis and contributes to chemo(radio)resistance [122]. STAT3 is a potential transcriptional regulator of the survivin gene and binds to the survivin promter at sites -264 to -256 [94]. Activation of STAT3 and survivin expression also confers resistance to chemotherapeutic agents (5-FU or cisplatin) in gastric cancer [123], hepatocellular carcinoma [124], NSCC [125] and ovarian cancer [104]. Survivin inhibitor MX106 effectively overcomes paclitaxel resistance in ovarian cancer cells [126]. In one study, STAT3 inhibition downregulated the expression of Bcl-xL, cyclin D1 and survivin,
and induced apoptosis in a hepatocellular carcinoma xenograft model. The study also demonstrated that STAT3 inhibition enhanced chemosensitivity to cisplatin [127].

STAT3/survivin signaling regulates a poor response to radiotherapy in HER2-positive breast cancer [67], ESCC [5] and lung cancer [75]. Treatment with linifanib resulted in the induction of cell death via apoptosis and reduced activation of STAT3. It also decreased the expression of cyclin D1 and survivin and overcame radioresistance of head and neck squamous cell carcinoma [93]. Furthermore, using an inhibitor of JAK2, which is upstream of STAT3, affected survivin expression and sensitized lung cancer to radiation in vitro and in vivo [75]. Thus, inhibiting the expression of pSTAT3 and survivin can be efficient in improving the response to chemo- and radiotherapy.

4.4. Cyclin D1

Cyclin D1 peaks during mid-G1 when growth factor-deprived cells re-enter the cell cycle. Previous reports demonstrate that cyclin D1 confers chemoresistance to several tumor cells [128–130]. Activated STAT3 increases cyclin D1 mRNA expression, and binds to the positions -984, -568, -239 and -27 in human cyclin D1 promoters [95]. Several studies reported that inhibition of the STAT3 signaling pathway reduced the expression of cyclin D1 and enhanced the drug sensitivity of the cancer cells, including gastric carcinoma [131], cholangiocarcinoma [132], bladder cancer [133] and hepatocellular carcinoma [134]. An antisense cyclin D1 sequence in head and neck squamous cell carcinoma (HSNCC) cells inhibits cell growth, induces apoptosis and enhances sensitivity to chemotherapeutic agents both in vitro and in vivo [135,136]. Furthermore, Muneyuki et al. revealed that the levels of pSTAT3 played a causative role in the overexpression of cyclin D1 and provided a poor prognosis in HNSCC [137]. The researchers also demonstrated that a dominant-negative STAT3 strongly enhanced the cellular sensitivity of HNSCC cells to 5-FU and radiation [138].

Cyclin D1 can be stimulated by low-dose ionizing radiation (LDIR) in human keratinocytes. Inhibition of cyclin D1 using siRNA can inhibit the LDIR-associated anti-apoptotic response and eliminate LDIR-induced adaptive radioresistance [139]. Radioresistant ESCC cells possessed the EMT characteristic with cyclin D1 overexpression. Inhibition of cyclin D1 by using siRNA significantly decreased the cell proliferation rate and resulted in G0/G1 arrest, and it also enhanced sensitivity to radiation and reversed EMT [140]. Pestell’s group investigated the effect of cyclin D1 on radiosensitivity in prostate cancer cells. Cyclin D1 promoted the clonogenic survival of LNCaP cells by 6-fold upon radiation. Cyclin D1 knockdown using shRNA resulted in a radiation-dose dependent precipitous decline in clonogenic survival. The data suggested that cyclin D1 promoted radioresistance in LNCaP cells [141]. Cyclin D1 has also been implicated in nasopharyngeal carcinoma (NPC), resulting in cell survival by the cyclin D1-dependent DNA repair machinery. Moreover, controlling cyclin D1 by knocking down insulinoma-associated protein1 enhanced the sensitivity of NPC cells to radiation both in vitro and in vivo [142].

4.5. Immunosuppressive Molecules

Activation of STAT3 is important for tumor-induced immunosuppression, which regulates the expression of immunosuppressive molecules [143]. Yu’s study showed that blocking STAT3 signaling with STAT3β or antisense STAT3 oligonucleotide activated dendritic cells (DCs) by inducing the proinflammatory mediators IL-6, regulated upon activation normal T cell expressed and secreted factor (RANTES) and interferon-inducible protein-10 (IP-10) in tumor cells [144]. Further, they revealed that the expression of MHC class II, CD80 and CD86 was increased in tumor-infiltrating DCs of STAT3-null mice [145]. Moreover, T cells, DCs and natural killer (NK) cells are immune cells that are directly involved in anti-tumor responses regardless of the tumor’s sensitivity to the STAT3 inhibitor [145]. STAT3 influenced the maturation of DCs involving Paxillin-3-forkhead (PAX3-FKHR)-expressing cells. PXA3-FKHR interacted with STAT3 to reduce the expression of MHC and generate immunoinhibitory secreted factors such as IL-10 in tumor cells. Thus, the altered transcription induced by the PAX3-FKHR-STAT3 complex suppressed local
inflammatory and immunological responses [146]. Another study demonstrated that tumor-derived factors prevented immature myeloid cells from differentiating into mature DCs via STAT3 activation. Except for the decrease in the expression of molecules (CD40, CD86) for T cell activation, the expression of MHC class II proteins also decreased [147].

IL-10 and TGF-β have been demonstrated to be involved in the suppression of the anti-tumor immune response of Treg cells [148]. Studies have reported that STAT3 bound to the promoters of the encoding genes of IL-10 [149] and TGF-β [150]. STAT3 is a key regulator of the Treg cells phenotype with the expression of IL-10, TGF-β and FOXP3 of nucleophosmin/anaplastic lymphoma kinase (NPM/ALK)-carrying T cell lymphoma (ALK+TCL) cells. IL-10 from ALK+TCL cells displays immunosuppressive activity, inhibits CD3/CD28 antibody-stimulated peripheral blood mononuclear cells and impairs the activation of T lymphocytes [151]. CD4+ CD25+ regulatory T cells are an important population of immunosuppressive cells. Treg cells from 12B1 tumor-bearing animals suppressed the function of DCs in a TGF-β- and IL-10-dependent manner and were associated with the activation of STAT3 [148]. Suppressor of cytokine signaling 3 (SOCS3)-deficient CD4+ T cells have a lower type 2 T helper cell (Th2) immune response and considerably increase the expression level of IL-10 and TGF-β for Th3-like differentiation via the enhanced recruitment of STAT3 to their promoters [150].

STAT3 has been identified on the promoter of vascular endothelial growth factor (VEGF) and was found to promote the growth and metastasis of human pancreatic cancer cells [152]. Chronic lymphocytic leukemia B cells secrete VEGF and activate the VEGF receptor (VEGFR). VEGF–VEGFR signaling is associated with abundant phosphorylated-STAT3 in the cell nucleus, which conferred apoptotic resistance to these cells [153]. Recently, Ong and colleagues found that a novel STAT3 mutation (p.D427H, E616G, p.E616K and p.E696K) increased phosphorylation of STAT3 at Tyr705 in STAT3 mutants. Further, p.E616K regulated programmed death-ligand 1 (PD-L1) expression via the binding of STAT3 to the promoter of PD-L1 in NK/T-cell lymphoma (NKTL). The team suggested that inhibitors of STAT3 and PD-L1 might be a promising therapeutic strategy for NKTL [154]. Castration-resistant prostate cancer (CRPC) cells increased the expression of PD-L1 which participated in tumor immune evasion under hypoxic conditions. Silencing STAT3 signaling can reverse the level of PD-L1 and enhance the susceptibility of CRPC cells to NK cell immunity [155].

5. The Alternative Splicing Product STAT3β

5.1. Antitumorigenic Potential of STAT3β

In various cells and tissues, the ratio of STAT3α to STAT3β ranges from 3:1 to 10:1 at the mRNA level, and from 1:3 to 10:1 at the protein level. Biehlmann and colleagues found that STAT3β was expressed at a high level in CD34+ cells by Western blot analysis [156–158]. Because of the low expression levels of STAT3β, its role remained elusive for a long time. Woude and colleagues reported that STAT3β had no effects on branching morphogenesis or invasion of leiomyosarcoma cells. However, STAT3β significantly inhibited cell growth in soft agar in a dose-dependent manner [159], while cell-specific STAT3β expression in macrophages reduced the invasion and cell mobility of breast cancer cells and significantly suppressed breast tumor growth [160].

Given a truncated C-terminal transactivation domain, transcriptional activation by STAT3β probably involves cooperation with other transcription factors, such as c-Jun and STRA13 [161–163]. STAT3β has more prolonged Y705 phosphorylation and nuclear retention kinetics than STAT3α, impacts STAT3α-dependent transcription and regulates a number of genes [21,164]. Cooperating with c-Jun, STAT3β increases Fas expression and the sensitization of melanoma cells to Fas ligand-induced apoptosis [161,165]. Zammarchi and colleagues revealed that the STAT3β switch leads to tumor regression in vivo. Furthermore, they revealed that STAT3β has its own specific set of target genes (such as Cyclin C, IL-8 and PEX1) and increases breast cancer cell death [166]. Transient transfection of STAT3β strongly inhibits transcriptional activation of c-Src dependent Bcl-xL [167]. As a potential antitumorigenic molecule, overexpression of STAT3β inhibits the transcriptional activity of STAT3α,
down-regulates the anti-apoptotic gene Bcl-xL and the cell cycle-related gene cyclin D1, and suppresses the proliferation of lung cancer cells [168]. In breast cancer cells, STAT3β mediates cells’ growth inhibition and leads to cell cycle arrest and apoptosis. Further, Niu and colleagues showed that STAT3β can induce the expression of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), which is a tumor-specific apoptotic effector [169]. Intriguingly, the expression of STAT3β can rescue the embryonic lethality of STAT3 deficient mice and induce the expression of specific STAT3 target genes [33].

STAT3β has gained attention as a potent tumor suppressor and a favorable prognostic factor in ESCC with or without chemoradiotherapy, and it strongly correlates with longer overall survival and recurrence-free survival [96]. Recently, it has been found that STAT3β correlates with a favorable prognosis and prolonged survival, and also has a tumor-suppressive effect in acute myeloid leukemia via the regulation of its target gene, SELK [170]. Taking these findings together, STAT3β is a potential protective prognostic marker.

5.2. STAT3β Switch Modulates Chemo(Radio)therapy Sensitivity

As mentioned earlier, STAT3β is a truncated form of STAT3α due to alternative splicing and could be of value if one could control STAT3 alternative splicing. Nevo-Caspi and colleagues show that the level of ADAR editing enzymes increases upon deferoxamine treatment in lymphoblastoid cells, elevating the level of editing in Alu sequences residing in STAT3 introns [171]. They further demonstrate that ADAR1 affects STAT3 alternative splicing by RNA editing, which increases the expression of STAT3β [172].

Few studies have focused on switching STAT3α to STAT3β, which contributes to the inhibition of cancer cell growth (Figure 2). As mentioned above, PCBP1 can regulate the proportion of STAT3α/STAT3β. PCBP1 inhibits oral squamous cell carcinoma cell growth and the expression of Bcl-xL and survivin, and it reverses the function of STAT3α [172, 173]. Recently, phosphorodiamidate morpholino oligomers (morpholinos) were targeted to a splicing enhancer, and then STAT3α was specifically switched to STAT3β, which led to apoptosis and cell cycle arrest in breast cancer cells [166]. The splicing reprogramming offers an effective therapeutic approach for cancer. Similar results were obtained by using STAT3α-to-β expression-switching oligonucleotides to inhibit breast cancer cell growth and migration [174].

STAT3 has been reported in chemoresistance and radioresistance. In contrast, STAT3β plays an essential tumor-suppressive role in cancer [19, 175]. Phosphorylation of STAT3 Ser727 is related to intrinsic radioresistance. STAT3β lacks the C-terminal 55 amino acids (containing S727), which indicates that STAT3β may enhance sensitivity to radiation. The roles of STAT3β in conferring radiation sensitivity to cells are still unclear to date [71, 176]. Currently, STAT3β has been shown to be involved in regulating chemoresistance. STAT3β-transfected gastric and breast cancer cells inhibited the invasion of gastric cancer cells, promoted apoptosis and improved sensitivity to chemotherapy [177]. Interestingly, STAT3β expression is correlated with overall survival and recurrence-free survival in esophageal squamous cell carcinoma (ESCC) patients with or without chemoradiotherapy and sensitizes tumor xenografts to chemotherapy (cisplatin and 5-FU) mainly by blocking the transcriptional activity of STAT3α [96]. Taken together, these findings indicated that STAT3β is a potential molecule for sensitization to chemo(radio)therapy in cancer patients.

6. STAT3 as a Therapeutic Target

Early clinical studies demonstrated the promise of therapy that targets STAT3. However, no inhibitors that directly target STAT3 have been approved by the FDA for clinical application. In the following section, we focus on inhibitors that directly target STAT3 through its N-terminal domain, DNA-binding domain, linker domain and SH2 domain (Figure 3).
6.1. Targeting the STAT3 N-Terminal Domain

The N-terminal domain is essential for DNA binding, nuclear translation and protein–protein interactions, and a crystal structure is available for designing STAT3 NTD inhibitors [178]. A structural study has suggested that the overall fold of the domain is similar for different STATs. STAT4 structural data and sequence homology are used to design peptide analogs of STAT3 helix 2. The peptide (DTRYLEQLHQLY) was found to directly and specifically bind to STAT3, as determined by fluorescence resonance energy transfer (FRET) in cells expressing GFP-STAT3. The derivative potently inhibited survival and induced apoptosis in breast cancer cells, but not normal breast cells [179]. Furthermore, ST3-H2A2 (LDTRYLEQLHKL) bound to both phosphorylated and unphosphorylated STAT3. Further studies are needed to fully understand the mechanism of action of these inhibitors.
survival and induced apoptosis in breast cancer cells, but not normal breast cells [179]. Furthermore, ST3-H2A2 (LDTRYLLEQLHKLY) bound to both phosphorylated and unphosphorylated STAT3 in prostate cancer cells, decreased STAT3 DNA binding ability and induced apoptotic cell death [180].

6.2. Targeting the STAT3 DNA-Binding Domain

Blocking STAT3 by targeting the DBD domain could affect DNA binding ability and has the potential to inhibit STAT3-dependent gene transcription. Galiellalactone (Figure 3a), a natural product, was isolated from fermentations of the ascomycete strain A111-95. It can block IL-6 signaling by binding to the DNA binding sites of activated STAT3 dimers, but it does not affect the activation of STAT3 Tyr701 and Ser727 [181]. These anticancer agents have been investigated in prostate cancer cells and stem cell-like ALDH-positive prostate cancer cells both in vivo and in vitro. They led to a reduction in anti-apoptotic or cell cycle regulatory proteins through the inhibition of STAT3 signaling [182,183]. In a study on the effectiveness of galiellalactone in prostate cancer cells, Don-Doncow et al. showed that it acts as a cysteine reactive inhibitor and binds to one or more cysteines in STAT3 (Cys-367, Cys-468, Cys-542). The compound could lead to the inhibition of STAT3 binding to DNA [184]. Recently, it was shown to suppress the resistance of prostate cancer cells to enzalutamide [185], and its analogs SG-1709 (Figure 3b) and SG-1721 (Figure 3c) exhibited even greater effectiveness in blocking STAT3 signaling and inducing apoptosis. Interestingly, SG-1721 combined with radiotherapy showed enhanced apoptosis in triple-negative breast cancer cells [186]. To deal with the oral bioavailability of galiellalactone, the galiellalactone prodrug GPA512 (Figure 3d) was synthesized and shown to be able to reduce tumor growth in vivo through oral administration. The effect of GPA512 was similar to that of galiellalactone [187].

Niclosamide, an FDA-approved anthelmintic drug, as well as other small-molecule inhibitors, inhibits STAT3 activity. In combination with radiation, it can overcome the radioresistance of lung cancer xenografts [59]. Even though it potently inhibits the activation and transcriptional function of STAT3, its poor aqueous solubility and bioavailability limit its clinical development. A series of novel O-alkylamino-tethered niclosamide derivatives have been designed, with one, denoted HJC0152, being able to suppress breast cancer cell tumor growth in vivo. Its excellent aqueous solubility means that it can be taken orally in clinical cancer therapy [188].

Structure-based drug design and computational docking have been used for screening small-molecule inhibitors that target the DNA-binding domain of STAT3. The DBD-binding drug inS3-54 (Figure 3e) selectively inhibits the DNA-binding activity of STAT3, but it has off-target effects. The same team further designed an improved lead compound (inS3-54A18, Figure 3f) that not only binds to DBD directly, but also inhibits the expression of downstream STAT3 target genes. Its oral availability and anti-tumor effects in lung xenograft models argue against the previously thought “undruggable” nature of a DBD [189,190]. Ligand-based pharmacophore models of STAT3 inhibitors are being used in combination with a 3D shape- and electrostatic-based drug approach. LC28 is identified as a STAT3 DBD inhibitor through the pharmacophore of the inS3-45 analog A18. The compound inhibits the survival of cisplatin-resistant ovarian cancer cells [191]. An LC28 analog, MMPP exhibits the strongest binding affinity to STAT3 and binds selectively to the DBD, especially to T456. MMPP effectively inhibits STAT3 in vitro and in vivo and induces G1-phase cell cycle arrest and apoptosis [192]. On the basis of the conjugation of a diarylidenyl-piperidone (DAP) backbone to a nitroxide precursor, Kellie identified a novel small-molecule inhibitor, HO-3867, a curcumin analog that directly interacts with the STAT3 DNA-binding domain. HO-3867 has been studied in ovarian and pancreatic cancer cells, and in an ovarian cancer xenograft mouse model [193–195]. A molecular dynamics simulation was used for virtual ligand screening of a chemical library, and Buettner et al. found that C48 is a STAT3 inhibitor that selectively binds to Cys468 of STAT3 and blocks phosphorylation of STAT3 to inhibit tumor growth in vivo [196].
6.3. Targeting the STAT3 Linker Domain

Researchers have found a small-molecule inhibitor of the STAT3 linker domain. Tatsuya et al. identified the benzoquinone derivative BPMB as a STAT3 inhibitor. BPMB could selectively inhibit proliferation in constitutively-activated STAT3 breast cancer cells. From an analysis by matrix-assisted laser desorption/ionization-mass spectrometry, Cys550 was found to be an important residue for crosslinking between STAT3 and BPMB. Cys550 could be a drug target for the development of irreversible STAT3 inhibitors [197]. Furthermore, Berg and colleagues identified catechol bisphosphate as a STAT5b inhibitor that exhibited a higher degree of selectivity than STAT5a, which was determined by the linker domain (position 566). Given the homology of the STAT family, it is extremely likely that the linker domain governs selectivity in a similar manner in STAT3 [198].

6.4. Targeting the STAT3 SH2 Domain

Phosphorylation of tyrosine residues in the SH2 domain of STAT3 is essential for receptor recognition as well as dimerization. In a search to identify small molecule inhibitors of STAT3, an SH2 domain-binding phosphopeptide PY*LKTK (Y* represents phosphotyrosine) was identified and formed inactive STAT3-PY*LKTK complexes. It has significant in vivo activity and suppresses v-Src transformation by blocking STAT3 signaling [20]. Since the first peptide inhibitor of STAT3 was identified, a number of small-molecule inhibitors that inhibit STAT3 have been demonstrated. On the basis of the lead compound PY*L (PY*LKTK tripeptide), Turkson found a selective and more potent peptide mimic, denoted ISS 610. It disrupts STAT3 activity in vitro, inhibits cell growth and induces apoptosis in Src-transformed fibroblasts [199]. Derived from the STAT3 SH2 domain, peptide mimic SPI has been tested in pancreatic, breast, prostate and non-small lung cancer cells. SPI was shown to have good effectiveness, including viability loss and apoptosis, in all cell lines tested [200]. Other peptides and phosphopeptide mimetics have been reported and used in cancer cells, such as CJ-1383 and PM-73G. Both can selectively inhibit STAT3. CJ-1383 induced breast cancer cell apoptosis in a dose-dependent manner, while inhibition of tumor growth by the phosphopeptide mimic PM-73G occurred without apoptosis or changes in the expression of cyclin D1 or survivin in xenograft models [201].

High-throughput screening of chemical libraries and computational docking studies have been used to discover inhibitors of STAT3. Statitic (6-nitro-benzo(b)thiophene-1,1-dioxide 1) was found to bind to the STAT3 SH2 domain. Another study demonstrated that Statitic enhanced radiosensitivity [202,203]. STA-21 (Figure 3g), a natural product analog of tetrangomycin, was discovered via structure-based virtual screening to bind to the SH2 domain and form hydrogen bonds with Arg595, Arg609 and Ile634 [204]. Phase I/II clinical trials (NCT01047943, 13 January 2010) for STA-21 have been performed for the treatment of psoriasis [205,206]. Analogs of STA-21 were reported later, such as LLL-3 (Figure 3h) and LLL-12 (Figure 3i), which can suppress cancer cell proliferation and induce apoptosis [207–209]. Using in silico site-directed fragment-based drug design (FBDD), the small-molecule STAT3 inhibitor LY5 (Figure 3j), an analog of STA-21, was tested in colon cancer cells. LY5 inhibited STAT3 phosphorylation and suppressed colon tumor growth in vivo [210]. The results suggest that LY5 can be an effective agent in cancer patients with constitutive activation of STAT3, and represents a promising approach for overcoming drug resistance induced by feedback activation of STAT3.

S3I-201 (NSC 74859, Figure 3k) is a selective chemical probe inhibitor of STAT3 and binds to the STAT3 phosphotyrosine peptide (PY*LKT) with the potential to become a radiosensitizer for esophageal cancer radiotherapy [88,211]. S3I-201 alkylates multiple Cys residues of STAT3 (Cys 108, 259, 367, 542 and 687), and is identified as a non-selective alkylating agent due to its leaving group O-tosyl [212]. Molecular modeling, using S3I-201 as the lead compound, led to S3I-1757, which could interact with Y705 in the binding site of the SH2 domain and decrease nuclear phosphotyrosine STAT3 levels [213]. To optimize S3I-201, Steven et al. synthesized a large set of S3I-201 analogs, among which SF-1-066 (known as S3I-201.1066, Figure 3l) and SF-1-121 showed impressive potency in whole-cell viability assays, and SF-1-066 also induced an antitumor response in breast tumor xenografts [214,215].
Further improvement of the parent compound SF-1-066 led to BP-5-087 (Figure 3m), a highly potent and selective STAT3 SH2 domain inhibitor, and when used in combination with imatinib, it could reverse TKI-resistant CML [39]. BP-1-102 (Figure 3n), identified as an analog of SF-1-066 via computer-aided design, also exhibited similar effects in breast cancer xenografts [216]. BP-1-102 is orally bioavailable and detectable at the micrograms levels in tumor tissues, which is enough to inhibit tumor growth. Even though micromolar concentrations of BP-1-102 in plasma were detected, the blood levels exceeded the IC50 (inhibitory concentration 50%, 6.8 ± 0.8 µM) [216]. To reduce the pharmacokinetic lability of BP-1-102, SH-4-54 was designed as a STAT3 SH2 domain inhibitor, which showed better therapeutic efficacy than BP-1-102, and exhibited blood–brain barrier permeability and controlled glioma tumor growth [217].

More recently, OPB-31121 (Otsuka pharmaceuticals Co. ltd.) and OPB-51602, potent small molecule inhibitors of STAT3, were found to strongly inhibit STAT3 phosphorylation and lead to effective antitumor responses [218–221]. They interact with the SH2 domain of STAT3 with high affinity and inhibit STAT3 Y705 and S727 phosphorylation. Computational docking and molecular dynamics simulations were used to examine the binding of OPB-31121 to STAT3, and OPB-31121 bound to S636 and V637 residues without overlapping with other STAT3 inhibitors [221,222]. OPB-51602 can directly interfere with mitochondrial STAT3 and induce the formation of STAT3 proteotoxic aggregates that are lethal to cancer cells [223,224]. These two inhibitors show the most potential among STAT3 SH2 domain inhibitors to date, based on preclinical studies that describe antitumor ability against various cancers. Phase I/II clinical trials for both OPB-31121 and OPB-51602 have been completed. These include a Phase I clinical trial for OPB-31121 in advanced cancer and solid tumor in Korea (NCT00657176, 18 April 2008) [225] and the USA (NCT00955812, 12 February 2013) [226], a Phase I/II trial in patients with progressive hepatocellular carcinoma (NCT01406574, 8 June 2015), and a Phase I OPB-51602 clinical trial for hematological malignancies in Japan (NCT01344876, 8 June 2015) [221] and for refractory solid tumors (NCT01184807, 26 March 2014) [220].

6.5. The Challenge of STAT3 Inhibitors

Aberrant STAT3 activation is related to cell malignant transformation, tumor proliferation, differentiation and anti-apoptosis [175]. Thus, STAT3 is considered a promising target in the development of anti-tumor drugs. Clearly, an accumulating number of STAT3 inhibitors have been discovered, as mentioned above. Most of them are mainly in the preclinical stage for screening drug activity, with few pharmacological and toxicological studies in animals and few compounds used for clinical trial.

The peptide (DTRYLEQLHQLY) and ST3-H2A2 (LDTRYLEQLHKLY) provide an additional strategy in the discovery of anti-STAT3 therapeutic agents as a novel anticancer therapy. However, the mechanisms of the peptides’ interaction with the N-terminal domain of STAT3 still need to be investigated. The “undruggable” nature of a DBD has been proven druggable in the case of STAT3. Inhibitors targeting the DBD have been in a minor development stage and will face challenges. In recent years, silibinin has been shown to have unique characteristics whereby it binds directly with high affinity to both the SH2 domain and DBD of STAT3, making it a promising lead candidate for designing novel and effective STAT3 inhibitors [227]. Although few small-molecule inhibitors of the STAT3 linker domain have been discovered, STAT3 mutants with a mutation in the linker domain exhibit very weak transcriptional activity [228]. The linker domain between the DNA-binding domain and the SH2 domain offers a new strategy for developing small-molecule inhibitors of STAT3.

At present, the main focus is on STAT3 inhibitors that bind to the tyrosine phosphorylation site of the SH2 domain of STAT3. The general structure of the SH2 domain and the mode of phosphopeptide recognition are conserved. The site is rich in positively charged residues, which requires a high negative charge of small molecules [229]. Therefore, inhibitors for targeting the SH2 domain generally have large side effect and poor pharmacokinetic characteristics. Faced with this challenge, Zhang and co-workers recently identified allosteric sites and a modulator of the coiled-coil domain of STAT3 via AlloFinder.
The team confirmed that K116 both inhibited STAT3 Tyr705 and promoted apoptosis in a dose-dependent manner [230].

In summary, small-molecule STAT3 inhibitors have antitumor activities and inhibit STAT3 phosphorylation but are yet to be approved for clinical cancer therapy. Inhibitors that target the SH2 domain of STAT3, such as STA-21, OPB-31121 and OPB-51602, have completed Phase I/II studies. These compounds are expected to progress in further clinical trials in the future and pave a new avenue for cancer therapy. The inhibitors targeting STAT3 may induce unexpected side-effects because of the repression of STAT3β, and regulators and drugs for the regulation of STAT3 alternative splicing remain to be investigated.

7. Conclusions and future perspectives

Chemoradiotherapy represents an important treatment for cancers. However, the intrinsic and acquired resistances of drug or radiation treatment limit its effectiveness in the clinic. Current evidence indicates that STAT3 is an oncogene, is constitutively activated in a variety of cancers, and regulates resistance to chemotherapy and radiotherapy. Signal transduction pathways influencing radiosensitivity mainly upregulate anti-apoptotic and cell cycle genes, induce EMT or modulate DNA repair [54]. Targeting the STAT3 pathway alone or in combination with other drugs can reverse resistance to chemotherapy or radiotherapy to significantly improve the effectiveness of therapy [4,35,36,48]. These findings show STAT3 to be a promising molecular target for the treatment of cancer. Inhibitors of different STAT3 domains have been identified via the screening of chemical libraries and computational docking. At present, few inhibitors have completed Phase I/II clinical trials. It is extremely urgent and important that we discover clinically useful inhibitors that target STAT3.

Conversely, constitutively active STAT3 inhibits cell proliferation and invasion in PTEN-deficient cancer cells [231,232]. The anti-tumor effects of STAT3 have also been reported for p19ARF-negative hepatocytes [233]. As mentioned above, STAT3β functions as a tumor suppressor and sensitizes cancer cells and ESCC patients to chemotherapy. The conflicting functions of STAT3 in cancers further indicate that STAT3 inhibitors must be used cautiously and could lead to enhanced tumor progression. To date, the binding sites of STAT3 inhibitors have docked to the crystal structure of STAT3β. These inhibitors probably bind to both STAT3α and STAT3β, and the selective binding affinities have not been characterized. Because of the unique structures of STAT3α and STAT3β, drugs targeting the C-terminal domain can be developed. We hope that promising drugs that selectively target STAT3α are forthcoming and that these drugs can reduce the possibility of side effects.

Interestingly, the ratio of STAT3α/STAT3β impacts the fate of a tumor. Splicing mediators, oligonucleotides and morpholinos can switch STAT3α to STAT3β in several cancer cells. Hopefully, in the next few years, several drugs that induce the expression of STAT3β by affecting alternative splicing regulators and increase chemo- and radiotherapeutic efficiency will be successfully applied in the treatment of cancer patients.

Author Contributions: P.-L.Y., L.-X.L., E.-M.L. and L.-Y.X. contributed to the literature review and manuscript preparation. All authors have read and agreed to the published version of the manuscript.

Funding: The authors of the current report were supported by the National Natural Science Foundation of China (No. 81772532).

Acknowledgments: De-Chen Lin (Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA) polished the manuscript at the beginning.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

AKT protein kinase B  JAK Janus kinase
Arg arginine  KRAS Kirsten rat sarcoma 2 viral oncogene homolog
ATM ataxia telangiectasia mutated  lncRNA-SRLR sorafenib resistance-associated lncRNA in RCC
Bax Bcl2 associated X  MEK mitogen-activated protein kinase kinase 7
Bcl-2 B-cell lymphoma 2  NKTL NK/T-cell lymphoma
Bcl-xL B-cell lymphoma-extra large  MLS myxoid liposarcoma
BLACAT1 bladder cancer associated transcript 1  NTD amino-terminal domain
BL Burkitt lymphoma  NSCLC non-small-cell lung cancer
CCD coiled-coil domain  PCBP1 poly-C binding protein-1
CKS1B cyclin-dependent kinase regulatory subunit 1B  PD-L1 programmed death ligand 1
CML chronic myeloid leukemia  PEK phosphosino1-3 kinase
CRC colorectal cancer  PTEN phosphatase and tensin homolog
CRT chemoradiotherapy  RCC renal cell carcinoma
CSC cancer stem cell  ROS reactive oxygen species
DAP diarylidenyl-piperidone  RT radiation therapy
DBD DNA-binding domain  RTKs receptor tyrosine kinases
DC dendritic cell  Ser727 serine 727
EGF epidermal growth factor  SELL selectin L
EGFR epidermal growth factor receptor  SH2 Src homolog 2
EMT epithelial-mesenchymal transition  STAT signal transducer and activator of transcription
ESCC esophageal squamous-cell carcinoma  TAD transcriptional activation domain
FBDD fragment-based drug design  TGF-β transforming growth factor β
FN Fibronectin  TKIs tyrosine kinase inhibitors
FRET fluorescence resonance energy transfer  Twist1 twist basic helix loop helix transcription factor 1
GAS interferon γ-activated sequence  Val valine
GBM Glioblastoma  VEGFR vascular endothelial growth factor receptor
HER2 human epidermal growth factor receptor 2  Tyr705 tyrosine 705
IL-6 interleukin-6  Ile isoleucine

References

1. Hoek, J.; Bloemendal, K.M.; van der Velden, L.A.; van Diessen, J.N.; van Werkhoven, E.; Klop, W.M.; Tesselaar, M.E. Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas. *Cancers* 2016, 8, 21. [CrossRef]  [PubMed]

2. Shah, B.A.; Qureshi, M.M.; Logue, J.M.; Cooley, T.P.; Zaner, K.S.; Jalisi, S.; Truong, M.T. Assessing cumulative acute toxicity of chemoradiotherapy in head and neck cancer with or without induction chemotherapy. *Am. J. Otolaryngol.* 2017, 38, 456–461. [CrossRef]

3. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef]  [PubMed]

4. Spitzner, M.; Ebner, R.; Wolff, H.A.; Ghadimi, B.M.; Wienands, J.; Grade, M. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. *Cancers* 2014, 6, 1986–2011. [CrossRef]  [PubMed]

5. Sugase, T.; Takahashi, T.; Serada, S.; Fujimoto, M.; Hirama, T.; Kurihara, K.; Ohkawara, T.; Tanaka, K.; Miyazaki, Y.; Makino, T.; Kurokawa, Y.; et al. SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma. *Cancer Res.* 2017, 77, 6975–6986. [CrossRef]  [PubMed]

6. Wu, X.; Tang, W.; Marquez, R.T.; Li, K.; Highfill, C.A.; He, F.; Lian, J.; Lin, J.; Sachs, R.J.; Ji, M.; et al. Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. *Oncotarget* 2016, 7, 11708–11723. [CrossRef]  [PubMed]

7. Shuai, K.; Stark, G.R.; Kerr, I.M.; Darnell, J.E., Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. *Science* 1993, 261, 1744–1746. [CrossRef]

8. Loh, C.Y.; Arya, A.; Naema, A.F.; Wong, W.F.; Sethi, G.; Looi, C.Y. Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication. *Front. Oncol.* 2019, 9, 48. [CrossRef]
10. Xu, X.; Sun, Y.L.; Hoey, T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. *Science* 1996, 273, 794–797. [CrossRef]

11. Shuai, K.; Horvath, C.M.; Huang, L.H.T.; Qureshi, S.A.; Cowburn, D.; Darnell, J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. *Cell* 1994, 76, 821–828. [CrossRef]

12. Zhang, T.; Kee, W.H.; Seow, K.T.; Fung, W.; Cao, X. The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. * Mol. Cell. Biol.* 2000, 20, 7132–7139. [CrossRef]

13. Wegenka, U.M.; Buschmann, J.; Lutticken, C.; Heinrich, P.C.; Horn, F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. *Mol. Cell. Biol.* 1993, 13, 276–288. [CrossRef] [PubMed]

14. Akira, S.; Nishio, Y.; Inoue, M.; Wang, X.J.; Wei, S.; Matsusaka, T.; Yoshida, K.; Sudo, T.; Naruto, M.; Kishimoto, T. Molecular cloning of APRE, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. *Cell* 1994, 77, 63–71. [CrossRef]

15. Zhong, Z.; Wen, Z.; Darnell, J.E., Jr. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. *Science* 1994, 264, 95–98. [CrossRef]

16. Tian, S.S.; Lamb, P.; Seidel, H.M.; Stein, R.B.; Rosen, J. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. *Blood* 1994, 84, 1760–1764. [CrossRef] [PubMed]

17. Vaisse, C.; Halaas, J.L.; Horvath, C.M.; Darnell, J.E., Jr.; Stoffel, M.; Friedman, J.M. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. *Nat. Genet.* 1996, 14, 95–97. [CrossRef]

18. Lim, C.P.; Cao, X. Structure, function, and regulation of STAT proteins. *Mol. Biosyst.* 2006, 2, 536–550. [CrossRef]

19. Zhang, H.X.; Yang, P.L.; Li, E.M.; Xu, L.Y. STAT3beta, a distinct isoform from STAT3. *Biochem. J.* 2002, 370, 273–288. [CrossRef] [PubMed]

20. Turkson, J.; Ryan, D.; Kim, J.S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A.D.; et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Clin. Cancer Res.* 2012, 18, 6703–6715. [CrossRef] [PubMed]

21. Corvinus, F.M.; Orth, C.; Moriggl, R.; Tsareva, S.A.; Wagner, S.; Pfitzner, E.B.; Baus, D.; Kaufmann, R.; Huber, L.A.; Zatloukal, K.; et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. *Neoplasia* 2005, 7, 545–555. [CrossRef] [PubMed]

22. Park, J.W.; Han, C.R.; Zhao, L.; Willingham, M.C.; Cheng, S.Y. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. *Endocr. Relat. Cancer* 2016, 23, 53–63. [CrossRef]

23. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene* 2002, 21, 2000–2008. [CrossRef] [PubMed]

24. Zhao, M.; Gao, F.H.; Wang, J.Y.; Liu, F.; Yuan, H.H.; Zhang, W.Y.; Jiang, B. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. *Lung Cancer* 2011, 73, 366–374. [CrossRef]

25. Ho, P.L.; Lay, E.J.; Jian, W.; Parra, D.; Chan, K.S. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. *Cancer Res.* 2012, 72, 3135–3142. [CrossRef]

26. Haura, E.B.; Zheng, Z.; Song, L.; Cantor, A.; Bepler, G. Activated epidermal growth factor receptor-Stat3 signaling promotes tumor survival in vivo in non-small cell lung cancer. *Clin. Cancer Res.* 2005, 11, 8288–8294. [CrossRef]
31. Takeda, K.; Noguchi, K.; Shi, W.; Tanaka, T.; Matsumoto, M.; Yoshiida, N.; Kishimoto, T.; Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94, 3801–3804. [CrossRef] [PubMed]
32. Niwa, H.; Burdon, T.; Chambers, I.; Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998, 12, 2048–2060. [CrossRef] [PubMed]
33. Maritano, D.; Sugrue, M.L.; Tininini, S.; Dewilde, S.; Strebli, B.; Fu, X.; Murray-Tait, V.; Chiarle, R.; Poli, V. The STAT3 isoforms alpha and beta have unique and specific functions. Nat. Immunol. 2004, 5, 401–409. [CrossRef] [PubMed]
34. Sun, C.; Bernard, R. Feedback and redundancy in receptor tyrosine kinase signaling: Relevance to cancer therapies. Trends Biochem. Sci. 2014, 39, 465–474. [CrossRef] [PubMed]
35. Lee, H.J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H.J.; Settleman, J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26, 207–221. [CrossRef]
36. Li, G.; Zhao, L.; Li, W.; Fan, K.; Qian, W.; Hou, S.; Wang, H.; Dai, J.; Wei, H.; Guo, Y. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 2014, 5, 8317–8329. [CrossRef]
37. Yoon, Y.K.; Kim, H.P.; Han, S.W.; Oh, D.Y.; Im, S.A.; Bang, Y.J.; Kim, T.Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Mol. Carcinog. 2010, 49, 353–362. [CrossRef]
38. Cheon, S.K.; Kim, H.P.; Park, Y.L.; Jang, J.E.; Lim, Y.; Song, S.H.; Han, S.W.; Kim, T.Y. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. Mol. Oncol. 2018, 12, 1398–1409. [CrossRef]
39. Eiring, A.M.; Page, B.D.G.; Kraft, I.L.; Mason, C.C.; Vellore, N.A.; Resetca, D.; Zabriskie, M.S.; Zhang, T.Y.; Khorashad, J.S.; Engar, A.J.; et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015, 29, 586–597. [CrossRef]
40. Zhao, C.; Xiao, H.; Wu, X.; Li, C.; Liang, G.; Yang, S.; Lin, J. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget 2015, 6, 14472–14487. [CrossRef]
41. Van Schaeybroeck, S.; Kalimutho, M.; Dunne, P.D.; Carson, R.; Allen, W.; Jithesh, P.V.; Redmond, K.L.; Sasazuki, T.; Shirasawa, S.; Blayney, J.; et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer cell. Cell Rep. 2014, 7, 1940–1955. [CrossRef] [PubMed]
42. Le Naour, A.; Mevel, R.; Thibault, B.; Courtais, E.; Chantalat, E.; Delord, J.P.; Couderc, B.; Guillermet-Guibert, J.; Martinez, A. Effect of combined inhibition of p110 alpha PI3K isofrom and STAT3 pathway in ovarian cancer platinum-based resistance. Oncotarget 2018, 9, 27220–27232. [CrossRef] [PubMed]
43. Tao, L.; Huang, G.; Wang, R.; Pan, Y.; He, Z.; Chu, X.; Song, H.; Chen, L. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-1R/STAT3 signaling pathway. Sci. Rep. 2016, 6, 38408. [CrossRef] [PubMed]
44. Ara, T.; Nakata, R.; Sheard, M.; Shimada, H.; Buettner, R.; Groschen, S.; Ji, L.; Yu, H.; Jove, R.; Seeger, R.; et al. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013, 73, 3852–3864. [CrossRef] [PubMed]
45. Mirzaei, A.; Mohammadi, S.; Ghaffari, S.H.; Nikbakht, M.; Bashash, D.; Alimoghaddam, K.; Ghavamzadeh, A. Osteopontin b and c isoforms: Molecular Candidates Associated with Leukemic Stem Cell Chemoresistance in Acute Myeloid Leukemia. Asian Pac. J. Cancer Prev. 2017, 18, 1707–1715. [CrossRef] [PubMed]
46. Sredni, B.; Weil, M.; Khomenok, G.; Lebenthal, I.; Teitz, S.; Mardor, Y.; Ram, Z.; Orenstein, A.; Kershenovich, A.; Michowiz, S.; et al. Ammonium trichloro(dioxoethylene-o,o’)-tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004, 64, 1843–1852. [CrossRef]
47. Prokoph, N.; Probst, N.A.; Lee, L.C.; Monahan, J.M.; Matthews, J.D.; Liang, H.C.; Bahnson, K.; Montes-Mojarro, I.A.; Karaca Atabay, E.; Sharma, G.G.; et al. IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. Blood 2020. [CrossRef]
48. Yang, Z.; Guo, L.; Liu, D.; Sun, L.; Chen, H.; Deng, Q.; Liu, Y.; Yu, M.; Ma, Y.; Guo, N.; et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 2015, 6, 5072–5087. [CrossRef]
49. Rokavec, M.; Oner, M.G.; Li, H.; Jackstadt, R.; Jiang, L.; Lodygin, D.; Kaller, M.; Horst, D.; Ziegler, P.K.; Schwitalla, S.; et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. *J. Clin. Investig.* 2014, 124, 1853–1867. [CrossRef]

50. Zhu, X.; Shen, H.; Yin, X.; Long, L.; Chen, X.; Feng, F.; Liu, Y.; Zhao, P.; Xu, Y.; Li, M.; et al. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. *Oncotarget* 2017, 8, 39154–39166. [CrossRef]

51. Zeng, R.; Tang, Y.; Zhou, H.; Liu, Y.; Huang, J.; Li, L.; Liu, W.; Feng, Y.; Zhou, Y.; Chen, T.; et al. STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback. *Biochem. Biophys. Res. Commun.* 2017, 488, 182–188. [CrossRef]

52. Roentgen, W.C. [On a new kind of ray (first report)]. *Munch. Med. Wochenschr.* (1950) 1959, 101, 1237–1239.

53. Thariat, J.; Hannoun-Levi, J.M.; Sun Myint, A.; Vuong, T.; Gerard, J.P. Past, present, and future of radiotherapy for the benefit of patients. *Nat. Rev. Clin. Oncol.* 2013, 10, 52–60. [CrossRef]

54. Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. *Nat. Rev. Cancer* 2011, 11, 239–253. [CrossRef] [PubMed]

55. Kim, B.M.; Hong, Y.; Lee, S.; Liu, P.; Lim, J.H.; Lee, Y.H.; Lee, T.H.; Chang, K.T.; Hong, Y. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. *Int. J. Mol. Sci.* 2015, 16, 26880–26913. [CrossRef]

56. Otero, D.C.; Poli, V.; Rickert, R.C. Cutting edge: Inherent and acquired resistance to radiation-induced apoptosis in B cells: A pivotal role for STAT3. *J. Immunol.* 2006, 177, 6593–6597. [CrossRef]

57. Li, X.; Wang, H.; Lu, X.; Di, B. Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo. *Exp. Ther. Med.* 2010, 1, 947–953. [CrossRef]

58. Wu, C.T.; Chen, M.F.; Chen, W.C.; Hsieh, C.C. The role of IL-6 in the radiation response of prostate cancer. *Radiat. Oncol.* 2013, 8, 159. [CrossRef] [PubMed]

59. You, S.; Li, R.; Park, D.; Xie, M.; Sica, G.L.; Cao, Y.; Xiao, Z.Q.; Deng, X. Disruption of STAT3 by niclosamide reverses radiosensitivity of human lung cancer. *Mol. Cancer Ther.* 2014, 13, 606–616. [CrossRef]

60. He, N.; Kong, Y.; Lei, X.; Liu, Y.; Wang, J.; Xu, C.; Wang, Y.; Du, L.; Ji, K.; Wang, Q.; et al. MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. *Cell Death Dis.* 2018, 9, 1026. [CrossRef] [PubMed]

61. Gao, L.; Li, F.S.; Chen, X.H.; Liu, Q.W.; Feng, J.B.; Liu, Q.J.; Su, X. Radiation induces phosphorylation of STAT3 in a dose- and time-dependent manner. *Asian Pac. J. Cancer Prev.* 2014, 15, 6161–6164. [CrossRef] [PubMed]

62. Chou, C.H.; Chen, P.J.; Jeng, Y.M.; Cheng, A.L.; Huang, L.R.; Cheng, J.C. Synergistic effect of radiation and interleukin-6 on hepatitis B virus reactivation in liver through STAT3 signaling pathway. *Int. J. Radiat. Oncol. Biol. Phys.* 2009, 75, 1545–1552. [CrossRef] [PubMed]

63. Yi, F.T.; Lu, Q.P. Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling. *Oncol. Lett.* 2017, 14, 7571–7576. [CrossRef] [PubMed]

64. Shi, Y.; Guryanova, O.A.; Zhou, W.; Liu, C.; Huang, Z.; Fang, X.; Wang, X.; Chen, C.; Wu, Q.; He, Z.; et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. *Sci. Transl. Med.* 2018, 10. [CrossRef] [PubMed]

65. Arnold, K.M.; Opdenaker, L.M.; Flynn, N.J.; Appeah, D.K.; Sims-Mourtada, J. Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells. *Int. J. Radiat. Biol.* 2020, 96, 434–447. [CrossRef]

66. Duru, N.; Fan, M.; Candas, D.; Menaa, C.; Liu, H.C.; Nantajit, D.; Wen, Y.; Xiao, K.; Eldridge, A.; Chromy, B.A.; et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. *Clin. Cancer Res.* 2012, 18, 6634–6647. [CrossRef]

67. Kim, J.S.; Kim, H.A.; Seong, M.K.; Seol, H.; Oh, J.S.; Kim, E.K.; Chang, J.W.; Hwang, S.G.; Noh, W.C. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. *Oncotarget* 2016, 7, 7055–7065. [CrossRef]

68. Lu, L.; Dong, J.; Wang, L.; Xia, Q.; Zhang, D.; Kim, H.; Yin, T.; Fan, S.; Shen, Q. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. *Oncogene* 2018, 37, 5292–5304. [CrossRef]
69. Oweida, A.J.; Darragh, L.; Phan, A.; Binder, D.; Bhatia, S.; Mueller, A.; Court, B.V.; Milner, D.; Raben, D.; Woessner, R.; et al. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. *J. Natl. Cancer Inst.* 2019, 111, 1339–1349. [CrossRef]

70. Karras, J.G.; Wang, Z.; Huo, L.; Howard, R.G.; Frank, D.A.; Rothstein, T.L. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. *J. Exp. Med.* 1997, 185, 1035–1042. [CrossRef]

71. Ouedraogo, Z.G.; Muller-Barthelemy, M.; Kemeny, J.L.; Dedieu, V.; Blau, J.; Khalil, T.; Raefelds, L.L.; Granzotto, A.; Pereira, B.; Beaudoin, C.; et al. STAT3 Serine 727 Phosphorylation: A Relevant Target to Radiosensitize Human Glioblastoma. *Brain Pathol.* 2016, 26, 18–30. [CrossRef] [PubMed]

72. Masliantsev, K.; Pinel, B.; Balbous, A.; Guichet, P.O.; Tachon, G.; Milin, S.; Godet, J.; Duchesne, M.; Berger, A.; et al. Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome. *Oncotarget* 2018, 9, 3968–3979. [CrossRef] [PubMed]

73. Purnell, P.R.; Mack, P.C.; Tepper, C.G.; Evans, C.P.; Green, T.P.; Gumerlock, P.H.; Lara, P.N.; Gandara, D.R.; Kung, H.J.; Gautschi, O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. *J. Thorac. Oncol.* 2009, 4, 448–454. [CrossRef] [PubMed]

74. Yin, Z.; Jin, F.G.; Liu, T.G.; Fu, E.Q.; Xie, Y.H.; Sun, R.L. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. *J. Surg. Res.* 2011, 171, 675–683. [CrossRef]

75. Sun, Y.; Moretti, L.; Giacalone, N.J.; Schleicher, S.; Speirs, C.K.; Carbone, D.P.; Lu, B. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. *J. Thorac. Oncol.* 2011, 6, 699–706. [CrossRef]

76. Chen, Y.W.; Chen, K.H.; Huang, P.I.; Chen, Y.C.; Chiou, G.Y.; Lo, W.L.; Tseng, L.M.; Hsu, H.S.; Chang, K.W.; Chiou, S.H. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44 (+)ALDH1 (+) cells. *Mol. Cancer Ther.* 2010, 9, 2879–2892. [CrossRef]

77. Kang, Y.; Park, M.A.; Heo, S.W.; Park, S.Y.; Kang, K.W.; Park, P.H.; Kim, J.A. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. *Biochim. Biophys. Acta* 2013, 1830, 2638–2648. [CrossRef]

78. Park, S.Y.; Lee, C.J.; Choi, J.H.; Kim, J.H.; Kim, J.W.; Kim, J.Y.; Nam, J.S. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. *J. Exp. Clin. Cancer Res.* 2019, 38, 399. [CrossRef]

79. Urick, M.E.; Chung, E.J.; Shield, W.P., 3rd; Gerber, N.; White, A.; Sowers, A.; Thetford, A.; Camphausen, K.; Mitchell, J.; Citrin, D.E. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. *Clin. Cancer Res.* 2011, 17, 5038–5047. [CrossRef]

80. Zang, C.; Liu, X.; Li, B.; He, Y.; Jing, S.; He, Y.; Wu, W.; Zhang, B.; Ma, S.; Dai, W.; et al. IL-6/STAT3/TWIST inhibition reverses ionizing radiation-induced EMT and radioresistance in esophageal squamous carcinoma. *Oncotarget* 2017, 8, 11228–11238. [CrossRef]

81. Yin, Z.; Zhang, Y.; Li, Y.; Lv, T.; Liu, J.; Wang, X. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. *Acta Histochem.* 2012, 114, 151–158. [CrossRef] [PubMed]

82. Lin, J.C.; Tsai, J.T.; Chao, T.Y.; Ma, H.I.; Liu, W.H. The STAT3/Slug Axis Enhances Radiation-Induced Tumor Invasion and Cancer Stem-like Properties in Radioresistant Glioblastoma. *Cancers* 2018, 10, 512. [CrossRef] [PubMed]

83. Lee, J.H.; Choi, S.I.; Kim, R.K.; Cho, E.W.; Kim, I.G. Tescalcin/c-Src/IGF1Rbeta-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1. *Sci. Rep.* 2018, 8, 10711. [CrossRef] [PubMed]

84. Chiang, P.K.; Tsai, W.K.; Chen, M.; Lin, W.R.; Chow, Y.C.; Lee, C.C.; Hsu, J.M.; Chen, Y.J. Zerumbone Regulates DNA Repair Responding to Ionizing Radiation and Enhances Radiosensitivity of Human Prostatic Cancer Cells. *Integr. Cancer Ther.* 2018, 17, 292–298. [CrossRef]

85. Yuan, S.S.; Hou, M.F.; Hsieh, Y.C.; Huang, C.Y.; Lee, Y.C.; Chen, Y.J.; Lo, S. Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer. *J. Natl. Cancer Inst.* 2012, 104, 1485–1502. [CrossRef]
86. Chen, X.; Chen, F.; Ren, Y.; Weng, G.; Xu, L.; Xue, X.; Keng, P.C.; Lee, S.O.; Chen, Y. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J. Cancer Res. Clin. Oncol. 2019, 145, 1471–1484. [CrossRef]
87. Zhang, Q.; Zhang, C.; He, J.; Guo, Q.; Hu, D.; Yang, X.; Wang, J.; Kang, Y.; She, R.; Wang, Z.; et al. STAT3 inhibitor statitic enhances radiosensitivity in esophageal squamous cell carcinoma. Tumour Biol. 2015, 36, 2135–2142. [CrossRef]
88. Huang, C.Y.; Lin, C.S.; Tai, W.T.; Hsieh, C.Y.; Shiau, C.W.; Cheng, A.L.; Chen, K.F. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 456–462. [CrossRef] [PubMed]
89. Saito, M.; Endo, K.; Furuya, S.; Minami, M.; Fukasawa, A.; Imamura, T.; Miyazawa, K. STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression. Oncogene 2016, 35, 1049–1057. [CrossRef] [PubMed]
90. Gu, L.; Chiang, K.Y.; Zhu, N.; Findley, H.W.; Zhou, M. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp. Hematol. 2007, 35, 957–966. [CrossRef] [PubMed]
91. Leslie, K.; Lang, C.; Devgavan, G.; Azare, J.; Berishaj, M.; Gerald, W.; Kim, Y.B.; Paz, K.; Darnell, J.E.; Albanese, C.; et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006, 66, 2544–2552. [CrossRef] [PubMed]
92. Zhang, H.F.; Chen, Y.; Wu, C.; Wu, Z.Y.; Tewardy, D.J.; Alshareef, A.; Liao, L.D.; Xue, Y.J.; Wu, J.Y.; Chen, B.; et al. The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3beta in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. 2016, 22, 691–703. [CrossRef]
93. Stephanou, A.; Brar, B.K.; Knight, R.A.; Latchman, D.S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 promoters. Cell Death Di. 2000, 7, 329–330. [CrossRef]
94. Rahaman, S.O.; Vogelbaum, M.A.; Haque, S.J. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13Ralpha2. Cancer Res. 2005, 65, 2956–2963. [CrossRef]
95. Isomoto, H.; Kobayashi, S.; Werneburg, N.W.; Bronk, S.F.; Guicciardi, M.E.; Frank, D.A.; Gores, G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42, 1329–1338. [CrossRef]
96. Yi, E.H.; Lee, C.S.; Lee, J.K.; Lee, Y.J.; Shin, M.K.; Cho, C.H.; Kang, K.W.; Lee, J.W.; Han, W.; Noh, D.Y.; et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol. Cancer Res. 2013, 11, 31–42. [CrossRef]
97. Fujita, Y.; Yagishita, S.; Hagiwara, K.; Yoshioka, Y.; Kosaka, N.; Takeshita, F.; Fujiwara, T.; Tsuta, K.; Nokihara, H.; Tamura, T.; et al. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol. Ther. 2015, 23, 717–727. [CrossRef] [PubMed]
98. Han, Z.; Feng, J.; Hong, Z.; Chen, L.; Li, W.; Liao, S.; Wang, X.; Ji, T.; Wang, S.; Ma, D.; et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem. Biophys. Res. Commun. 2013, 435, 188–194. [CrossRef] [PubMed]
99. Selvendiran, K.; Bratasz, A.; Tong, L.; Ignarro, L.J.; Kuppusamy, P. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 2008, 7, 81–88. [CrossRef] [PubMed]
100. Yan, H.; Guo, B.Y.; Zhang, S. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. Biochem. Biophys. Res. Commun. 2016, 470, 947–954. [CrossRef] [PubMed]
105. Hira, S.K.; Mondal, I.; Bhattacharya, D.; Gupta, K.K.; Manna, P.P. Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-alpha. *Int. J. Biochem. Cell Biol.* 2015, 67, 1–13. [CrossRef]

106. Meng, Y.; Tang, W.; Dai, Y.; Wu, X.; Liu, M.; Ji, Q.; Ji, M.; Pienta, K.; Lawrence, T.; Xu, L. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. *Mol. Cancer Ther.* 2008, 7, 2192–2202. [CrossRef]

107. Kiprianova, I.; Remy, J.; Milosch, N.; Mohrenz, I.V.; Seifert, V.; Aigner, A.; Kogel, D. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. *Neoplasia* 2015, 17, 564–573. [CrossRef]

108. Lian, J.; Ni, Z.; Dai, X.; Su, C.; Smith, A.R.; Xu, L.; He, F. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. *Mol. Cancer Ther.* 2012, 11, 416–426. [CrossRef]

109. Rosser, C.J.; Reyes, A.O.; Vakar-Lopez, F.; Levy, L.B.; Kuban, D.A.; Hoover, D.C.; Lee, A.K.; Pisters, L.L. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate cancer, compared with localized radio-naïve prostate carcinoma. *Inter. J. Radiat. Oncol. Biol. Phys.* 2003, 56, 1–6. [CrossRef]

110. Kong, Z.; Xie, D.; Boike, T.; Raghavan, P.;urma, S.; Chen, D.J.; Habib, A.A.; Chakraborty, A.; Hsieh, J.T.; Saha, D. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. *Cancer Res.* 2010, 70, 2829–2839. [CrossRef]

111. Van Staalduinen, J.; Baker, D.; Ten Dijke, P.; van Dam, H. Epithelial-mesenchymal-transition-inducing transcription factors: New targets for tackling chemoresistance in cancer? *Oncogene* 2018, 37, 6195–6211. [CrossRef] [PubMed]

112. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009, 139, 871–890. [CrossRef] [PubMed]

113. Chong, K.Y.; Kang, M.; Garofalo, F.; Ueno, D.; Liang, H.; Cady, S.; Madarikan, O.; Pitruzzello, N.; Tsai, C.H.; Yang, J.; Xing, H.; Hong, L.; Lu, D.H.; Li, B.S.; Tang, J.M.; Min, J. STAT3-mediated Twist1 upregulation contributes to epithelial-mesenchymal transition in cisplatin resistant ovarian cancer. *Am. J. Transl. Res.* 2019, 11, 4277–4289.

114. Liang, F.; Ren, C.; Wang, J.; Wang, S.; Yang, L.; Han, X.; Chen, Y.; Tong, G.; Yang, G. The crosstalk between STAT3 and p33/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. *Oncogenesis* 2019, 8, 59. [CrossRef]

115. Su, Y.K.; Bamodu, O.A.; Tseng, Y.M.; Hsiao, M.; Yeh, C.T.; Lin, C.M. Ovatodiolide inhibits the oncogenicity and cancer stem-like phenotype of glioblastoma cells, as well as potentiate the anticancer effect of temozolomide. *Phytomedicine* 2019, 61, 152840. [CrossRef]

116. Liu, S.C.; Huang, C.M.; Bamodu, O.A.; Lin, C.S.; Liu, B.L.; Tseng, Y.M.; Tsai, J.T.; Lee, W.H.; Chen, T.M. Ovatodiolide suppresses nasopharyngeal cancer by targeting stem cell-like population, inducing apoptosis, inhibiting EMT and dysregulating JAK/STAT signaling pathway. *Phytomedicine* 2019, 56, 269–278. [CrossRef]

117. Liang, H.; Chen, G.; Li, J.; Yang, F. Snail expression contributes to temozolomide resistance in glioblastoma. *Am. J. Transl. Res.* 2019, 11, 84–97. [CrossRef]

118. Wang, H.; Li, J.M.; Wei, W.; Yang, R.; Chen, D.; Ma, X.D.; Jiang, G.M.; Wang, B.L. Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer. *Cancer Sci.* 2020, 111, 56–67. [CrossRef]

119. Park, J.H.; Kim, Y.H.; Park, E.H.; Lee, S.J.; Kim, H.; Kim, A.; Lee, S.B.; Shim, S.; Jang, H.; Myung, J.K.; et al. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. *Cancer Sci.* 2019, 110, 2834–2845. [CrossRef]

120. Yang, J.; Xing, H.; Hong, L.; Li, D.H.; Li, B.S.; Tang, J.M.; Min, J. STAT3-mediated Twist1 upregulation contributes to epithelial-mesenchymal transition in cisplatin resistant ovarian cancer. *Int. J. Clin. Exp. Med.* 2018, 11, 6749–6757.

121. Wu, K.; Wang, B.; Chen, Y.; Zhou, J.; Huang, J.; Hui, K.; Zeng, J.; Zhu, J.; Zhang, K.; Li, L.; et al. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. *Cell Signal.* 2015, 27, 2515–2523. [CrossRef] [PubMed]

122. Mita, A.C.; Mita, M.M.; Nawrocki, S.T.; Giles, F.J. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. *Clin. Cancer Res.* 2008, 14, 5000–5005. [CrossRef] [PubMed]
Cancers 2020, 12, 2459

123. Pandey, A.; Vishnoi, K.; Mahata, S.; Tripathi, S.C.; Misra, S.P.; Misra, V.; Mehrotra, R.; Dwivedi, M.; Bharti, A.C. Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Flourouracil. *Nutr. Cancer* **2015**, *67*, 1293–1304. [CrossRef] [PubMed]

124. Wang, C.; Yang, M.; Zhao, J.; Li, X.; Xiao, X.; Zhang, Y.; Jin, X.; Liao, M. Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. *J. Cell. Physiol.* **2019**, *234*, 10899–10906. [CrossRef]

125. Hu, W.; Jin, P.; Liu, W. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin. *Cell. Physiol. Biochem.* **2016**, *38*, 1199–1208. [CrossRef] [PubMed]

126. Zhao, G.; Wang, Q.; Wu, Z.; Tian, X.; Yan, H.; Wang, B.; Dong, P.; Watari, H.; Pfeuffer, L.M.; Guo, Y.; et al. Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor. *Mol. Cancer Ther.* **2019**, *18*, 2233–2245. [CrossRef]

127. Lau, C.K.; Yang, Z.F.; Lam, S.P.; Lam, C.T.; Ngai, P.; Tam, K.H.; Poon, R.T.; Fan, S.T. Inhibition of Stat3 activity sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells. *J. Biol. Regul. Homeost. Agents* **2019**, *33*, 3572–3579. [CrossRef] [PubMed]

128. Biliran, H., Jr.; Wang, Y.; Banerjee, S.; Xu, H.; Heng, H.; Thakur, A.; Bollig, A.; Sarkar, F.H.; Liao, J.D. Bilirubin induces cell survival and tumor shrinkage in human squamous carcinomas. *Arch. Otolaryngol. Head Neck Surg.* **2000**, *126*, 957–961. [CrossRef] [PubMed]

129. Dong, X.F.; Liu, T.Q.; Zhi, X.T.; Zou, J.; Zhong, J.T.; Li, T.; Mo, X.L.; Zhou, W.; Guo, W.W.; Liu, X.; et al. COX-2/PGE2 Axis Regulates HIF2alpha Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment. *Clin. Cancer Res.* **2018**, *24*, 3204–3216. [CrossRef]

130. Shimura, T. Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy. *Int. J. Radiat. Biol.* **2017**, *93*, 381–385. [CrossRef] [PubMed]

131. Li, H.; Lu, H.; Lv, M.; Wang, Q.; Sun, Y. Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. *Oncol. Lett.* **2018**, *15*, 3572–3579. [CrossRef] [PubMed]

132. Fu, Z.; Ma, K.; Dong, B.; Zhao, C.; Che, C.; Dong, C.; Zhang, R.; Wang, H.; Wang, X.; Liang, R. The synergistic antitumor effect of Huaier combined with 5-Flourouracil in human cholangiocarcinoma cells. *BMC Complement. Altern. Med.* **2019**, *19*, 203. [CrossRef] [PubMed]

133. Lei, T.; Zhou, S.; Meng, Q.; Zhang, M. STAT3 signaling pathway in drug-resistant bladder cancer cell line. *J. Biol. Regul. Homeost. Agents* **2019**, *33*, 1347–1357. [CrossRef] [PubMed]

134. Tai, W.T.; Cheng, A.L.; Shiaw, C.W.; Liu, C.Y.; Ko, C.H.; Lin, M.W.; Chen, P.J.; Chen, K.F. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. *Mol. Cancer Ther.* **2012**, *11*, 452–463. [CrossRef] [PubMed]

135. Nakashima, T.; Clayman, G.L. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. *Arch. Otolaryngol. Head Neck Surg.* **2000**, *126*, 957–961. [CrossRef] [PubMed]

136. Sauter, E.R.; Nesbit, M.; Litwin, S.; Klein-Szanto, A.J.; Cheffetz, S.; Herlyn, M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. *Cancer Res.* **1999**, *59*, 4876–4881.

137. Masuda, M.; Suzuki, M.; Yasumatu, R.; Nakashima, T.; Kuratomi, Y.; Azuma, K.; Tomita, K.; Komiya, S.; Weinstein, I.B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. *Cancer Res.* **2002**, *62*, 3351–3355.

138. Masuda, M.; Toh, S.; Koike, K.; Kuratomi, Y.; Suzuki, M.; Deguchi, A.; Komiya, S.; Weinstein, I.B. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. *Int. J. Cancer Res.* **2002**, *93*, 329–339. [CrossRef]

139. Ahmed, K.M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J.J. Cyclin D1 in low-dose radiation-induced adaptive resistance. *Oncogene* **2008**, *27*, 6738–6748. [CrossRef]

140. Su, H.; Jin, X.; Shen, L.; Fang, Y.; Fei, Z.; Zhang, X.; Xie, C.; Chen, X. Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells. *Tumour Biol.* **2016**, *37*, 5355–5363. [CrossRef]
141. Casimiro, M.C.; Di Sante, G.; Ju, X.; Li, Z.; Chen, K.; Crosariol, M.; Yaman, I.; Gormley, M.; Meng, H.; Lisanti, M.P.; et al. Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. *Cancer Res.* 2016, 76, 329–338. [CrossRef]

142. Song, R.; Wei, X.; Wang, Y.; Hu, S.; Ba, Y.; Xiao, X.; Zhang, J. Insulinoma-associated protein 1 controls nasopharyngeal carcinoma to radiotherapy by modulating cyclin D1-dependent DNA repair machinery. *Carcinogenesis* 2020, 41, 326–333. [CrossRef] [PubMed]

143. Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. *Nat. Rev. Immunol.* 2007, 7, 41–51. [CrossRef]

144. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Keller, H.; Coppola, D.; et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. *Nat. Med.* 2004, 10, 48–54. [CrossRef] [PubMed]

145. Nefedova, Y.; Huang, M.; Kusmartsev, S.; Bhattacharya, R.; Cheng, P.; Salup, R.; Jove, R.; Gabrilovich, D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. *J. Immunol.* 2004, 172, 464–474. [CrossRef]

146. Larmonier, N.; Marron, M.; Zeng, Y.; Cantrell, J.; Romanoski, A.; Sepassi, M.; Thompson, S.; Chen, X.; Andreansky, S.; Katsanis, E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. *Cancer Immunol. Immunother.* 2007, 56, 48–59. [CrossRef]

147. Benkhart, E.M.; Siedlar, M.; Wedel, A.; Werner, T.; Ziegler-Heitbrock, H.W. Role of Stat3 in hyperactivation of T helper cells resulted in reduced immune responses against tumor cells. *Mol. Med. Rep.* 2018, 12, 1146–1158. [CrossRef]

148. Wei, D.; Le, X.; Zheng, L.; Wang, L.; Frey, J.A.; Gao, A.C.; Peng, Z.; Huang, S.; Xiong, H.Q.; Abbruzzese, J.L.; et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. *Carcinogenesis* 2003, 24, 2659–2669. [CrossRef]

149. Kinjyo, I.; Inoue, H.; Hamano, S.; Fukuyama, S.; Yoshimura, T.; Koga, K.; Takaki, H.; Himeno, K.; Takaesu, G.; Kobayashi, T.; et al. Loss of SOCS3 in T helper cells interact with STAT 1 and 3: Implication for apoptosis resistance. *Oncogene* 2004, 23, 9964–9969. [CrossRef] [PubMed]

150. Kerr, W.G.; et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. *Nat. Med.* 2005, 11, 1314–1321. [CrossRef] [PubMed]

151. Kasprzycka, M.; Marzec, M.; Liu, X.; Zhang, Q.; Wasik, M.A. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. *Proc. Natl Acad. Sci. USA* 2006, 103, 9964–9969. [CrossRef] [PubMed]

152. Wei, D.; Le, X.; Zheng, L.; Wang, L.; Frey, J.A.; Gao, A.C.; Peng, Z.; Huang, S.; Xiong, H.Q.; Abdurrazzak, J.L.; et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. *Oncogene* 2003, 22, 319–329. [CrossRef] [PubMed]

153. Lee, Y.K.; Shanafelt, T.D.; Bone, N.D.; Strege, A.K.; Jelinek, D.F.; Kay, N.E. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT1 and 3: Implication for apoptosis resistance. *Leukemia* 2005, 19, 513–523. [CrossRef] [PubMed]

154. Song, T.L.; Nairsmagi, M.L.; Laurensia, Y.; Lim, J.Q.; Tan, J.; Li, Z.M.; Pang, W.L.; Kizhakeyil, A.; Wijaya, G.C.; Huang, D.C.; et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. *Blood* 2018, 132, 1146–1158. [CrossRef]

155. Xu, L.J.; Ma, Q.; Zhu, J.; Li, J.; Xue, B.X.; Gao, J.; Sun, C.Y.; Zang, Y.C.; Zhou, Y.B.; Yang, D.R.; et al. Combined inhibition of JAK1,2/STAT3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. *Mol. Med. Rep.* 2018, 17, 8111–8120. [CrossRef]

156. Shao, H.; Quintero, A.J.; Tweardy, D.J. Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing. *Blood* 2001, 98, 3853–3856. [CrossRef]

157. Biethahn, S.; Alves, F.; Wilde, S.; Hiddemann, W.; Spiekermann, K. Expression of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. *Exp. Hematol.* 1999, 27, 885–894. [CrossRef]

158. Chakraborty, A.; White, S.M.; Schaefer, T.S.; Ball, E.D.; Dyer, K.F.; Tweardy, D.J. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. *Blood* 1996, 88, 2442–2449. [CrossRef]
159. Zhang, Y.W.; Wang, L.M.; Jove, R.; Vande Woude, G.F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. *Oncogene* 2002, 21, 217–226. [CrossRef]

160. Dang, W.; Tang, H.; Cao, H.; Wang, L.; Zhang, X.; Tian, W.; Pang, X.; Li, K.; Chen, T. Strategy of STAT3beta cell-specific expression in macrophages exhibits antitumor effects on mouse breast cancer. *Gene Ther.* 2015, 22, 977–983. [CrossRef]

161. Schaefer, T.S.; Sanders, L.K.; Nathans, D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. *Proc. Natl. Acad. Sci. USA* 1995, 92, 9097–9101. [CrossRef] [PubMed]

162. Schaefer, T.S.; Sanders, L.K.; Park, O.K.; Nathans, D. Functional differences between Stat3alpha and Stat3beta. *Mol. Cell. Biol.* 1997, 17, 5307–5316. [CrossRef] [PubMed]

163. Ivanova, A.V.; Ivanov, S.V.; Zhang, X.; Ivanov, V.N.; Timofeeva, O.A.; Lerman, M.I. STRA13 interacts with STAT3 and modulates transcription of STAT3-dependent targets. *J. Mol. Biol.* 2004, 340, 641–653. [CrossRef] [PubMed]

164. Ng, I.H.; Bogoyevitch, M.A.; Jans, D.A. Cytokine-induced slowing of STAT3 nuclear import; faster basal trafficking of the STAT3beta isoform. *Traffic* 2014, 15, 946–960. [CrossRef] [PubMed]

165. Ivanov, V.N.; Krasilnikov, M.; Ronai, Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. *J. Biol. Chem.* 2002, 277, 4932–4944. [CrossRef]

166. Zammarchi, F.; de Stanchina, E.; Bournazou, E.; Supakorndej, T.; Martires, K.; Riedel, E.; Corben, A.D.; Ivanov, V.N.; Krasilnikov, M.; Ronai, Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. *J. Biol. Chem.* 2002, 277, 4932–4944. [CrossRef]

167. Karni, R.; Jove, R.; Levitzki, A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. *Oncogene* 1999, 18, 4654–4662. [CrossRef]

168. Xu, G.; Zhang, C.; Zhang, J. Dominant negative STAT3 suppresses the growth and invasion capability of Zammarchi, F.; de Stanchina, E.; Bournazou, E.; Supakorndej, T.; Martires, K.; Riedel, E.; Corben, A.D.; Ivanov, V.N.; Krasilnikov, M.; Ronai, Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. *J. Biol. Chem.* 2002, 277, 4932–4944. [CrossRef]

169. Niu, G.; Shain, K.H.; Huang, M.; Ravi, R.; Bedi, A.; Dalton, W.S.; Jove, R.; Yu, H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. *Cancer Res.* 2001, 61, 3276–3280.

170. Aigner, P.; Mizutani, T.; Xu, G.; Zhang, C.; Zhang, J. Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. *Mol. Med. Rep.* 2009, 2, 819–824. [CrossRef]

171. Nevo-Caspi, Y.; Amariglio, N.; Rechavi, G.; Paret, G.; Nevo-Caspi, Y. A-to-I RNA editing is induced upon hypoxia. *Blood Adv.* 2019, 3, 1089–1020. [CrossRef]

172. Goldberg, L.; Abutbul-Amitai, M.; Paret, G.; Nevo-Caspi, Y. Alternative Splicing of STAT3 Is A phenotypical phenotype of cells overexpressing EGF and HER-2 receptors. *Oncogene* 1999, 18, 4654–4662. [CrossRef]

173. Wang, X.; Guo, J.; Che, X.; Jia, R. PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. *Mol. Cell. Biol.* 2015, 35, 3284–3300. [CrossRef]

174. Tano, V.; Jans, D.A.; Bogoyevitch, M.A. Oligonucleotide-directed STAT3 alternative splicing switch drives anti-tumorigenic outcomes in MCF10 human breast cancer cells. *Biochem. Biophys. Res. Commun.* 2019, 513, 1076–1082. [CrossRef] [PubMed]

175. Aigner, P.; Just, V.; Stoiber, D. STAT3 isoforms: Alternative fates in cancer? *Cytokine* 2019, 118, 27–34. [CrossRef] [PubMed]

176. Drubay, V.; Skrypek, N.; Cordiecz, L.; Vasseur, R.; Schulz, C.; Boukrout, N.; Duchene, B.; Coppin, L.; Van Seuningen, I.; Jonckheere, N. TGF-betaRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. *Cancers* 2018, 10, 254. [CrossRef] [PubMed]

177. Banerjee, A.S.; Pal, A.D.; Banerjee, S. Epstein-Barr virus-encoded small non-coding RNAs induce cancer cell chimoresistance and migration. *Virology* 2013, 443, 294–305. [CrossRef] [PubMed]

178. Hu, T.; Yeh, J.E.; Pinello, L.; Jacob, J.; Chakravarthy, S.; Yuan, G.C.; Chopra, R.; Frank, D.A. Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. *Mol. Cell. Biol.* 2015, 35, 3284–3300. [CrossRef]

179. Timofeeva, O.A.; Gaponenko, V.; Lockett, S.J.; Tarasov, S.G.; Jiang, S.; Michejda, C.J.; Perantoni, A.O.; Tarasova, N.I. Rationally designed inhibitors identify STAT3-N-domain as a promising anticancer drug target. *ACS Chem. Biol.* 2007, 2, 799–809. [CrossRef]
180. Timofeeva, O.A.; Tarasova, N.I.; Zhang, X.; Chasovskikh, S.; Cheema, A.K.; Wang, H.; Brown, M.L.; Dritschilo, A. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 1267–1272. [CrossRef]

181. Weidler, M.; Rether, J.; Anke, T.; Erkel, G. Inhibition of interleukin-6 signaling by galiellalactone. *FEBS Lett.* **2000**, *484*, 1–6. [CrossRef]

182. Hellsten, R.; Johansson, M.; Dahlman, A.; Dizeyi, N.; Sterner, O.; Bjartell, A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. *Prostate* **2008**, *68*, 269–280. [CrossRef] [PubMed]

183. Hellsten, R.; Johansson, M.; Dahlman, A.; Sterner, O.; Bjartell, A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. *PLoS ONE* **2011**, *6*, e22118. [CrossRef] [PubMed]

184. Don-Doncow, N.; Escobar, Z.; Johansson, M.; Kjellstrom, S.; Garcia, V.; Munoz, E.; Sterner, O.; Bjartell, A.; Hellsten, R. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. *J. Biol. Chem.* **2014**, *289*, 15969–15978. [CrossRef]

185. Thaper, D.; Vahid, S.; Kaur, R.; Kumar, S.; Nouruzi, S.; Bishop, J.L.; Johansson, M.; Zoubeidi, A. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. *Sci. Rep.* **2018**, *8*, 17307. [CrossRef]

186. Ko, H.; Lee, J.H.; Kim, H.S.; Kim, T.; Han, Y.T.; Suh, Y.G.; Chun, J.; Kim, Y.S.; Ahn, K.S. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer. *Biomolecules* **2019**, *9*, 170. [CrossRef]

187. Escobar, Z.; Bjartell, A.; Canesin, G.; Evans-Axelson, S.; Sterner, O.; Hellsten, R.; Johansson, M.H. Preclinical Characterization of 3beta-(N-Acetyl l-cysteine methyl ester)-2alpha,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. *J. Med. Chem.* **2016**, *59*, 4551–4562. [CrossRef]

188. Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J. Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. *ACS Med. Chem. Lett.* **2013**, *4*, 180–185. [CrossRef]

189. Huang, W.; Dong, Z.; Wang, F.; Peng, H.; Liu, J.Y.; Zhang, J.T. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. *ACS Chem. Biol.* **2014**, *9*, 1188–1196. [CrossRef]

190. Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C.J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. *Oncogene* **2016**, *35*, 783–792. [CrossRef]

191. Huang, W.; Liu, Y.; Wang, J.; Yuan, X.; Jin, H.W.; Zhang, L.R.; Zhang, J.T.; Liu, Z.M.; Cui, J.R. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. *Eur. J. Med. Chem.* **2018**, *157*, 887–897. [CrossRef] [PubMed]

192. Son, D.J.; Zheng, J.; Jung, Y.Y.; Hwang, C.J.; Lee, H.P.; Woo, J.R.; Baek, S.Y.; Ham, Y.W.; Kang, M.W.; Shong, M.; et al. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain. *Theranostics* **2017**, *7*, 4632–4642. [CrossRef] [PubMed]

193. Selvendiran, K.; Ahmed, S.; Dayton, A.; Kuppusamy, M.L.; Rivera, B.K.; Kalai, T.; Hideg, K.; Kuppusamy, P. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. *Cancer Biol. Ther.* **2011**, *12*, 837–845. [CrossRef] [PubMed]

194. Mast, J.M.; Tse, D.; Shee, K.; Lakshmi Kuppusamy, M.; Kmiec, M.M.; Kalai, T.; Kuppusamy, P. Diarylidendipiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells. *Cell Biochem. Biophys.* **2019**, *77*, 109–119. [CrossRef]

195. Selvendiran, K.; Tong, L.; Bratasz, A.; Kuppusamy, M.L.; Ahmed, S.; Ravi, Y.; Trigg, N.J.; Rivera, B.K.; Kalai, T.; Hideg, K.; et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. *Mol. Cancer Ther.* **2010**, *9*, 1169–1179. [CrossRef]

196. Buettner, R.; Corzano, R.; Rashid, R.; Lin, J.; Senthil, M.; Hedvat, M.; Schroeder, A.; Mao, A.; Herrmann, A.; Yim, J.; et al. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. *ACS Chem. Biol.* **2011**, *6*, 432–443. [CrossRef]

197. Koseki, T.; Suehiro, N.; Masuda, Y.; Miyoshi, N.; Muraoka, D.; Ogo, N.; Asai, A. Discovery of a New STAT3 Inhibitor Acting on the Linker Domain. *Biol. Pharm. Bull.* **2019**, *42*, 792–800. [CrossRef]
198. Grab, J.; Berg, A.; Blechschmidt, L.; Kluver, B.; Rubner, S.; Fu, D.Y.; Meiler, J.; Graber, M.; Berg, T. The STAT5b Linker Domain Mediates the Selectivity of Catechol Bisphosphates for STAT5b over STAT5a. ACS Chem. Biol. 2019, 14, 796–805. [CrossRef]

199. Turkson, J.; Kim, J.S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A.D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 2004, 3, 261–269.

200. Zhao, W.; Jaganathan, S.; Turkson, J. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J. Biol. Chem. 2010, 285, 35855–35865. [CrossRef]

201. Auzenne, E.J.; Klostergaard, J.; Mandal, P.K.; Liao, W.S.; Lu, Z.; Gao, F.; Bast, R.C., Jr.; Robertson, F.M.; McMurray, J.S. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J. Exp. Ther. Oncol. 2012, 10, 155–162. [PubMed]

202. Schust, J.; Sperl, B.; Hollis, A.; Mayer, T.U.; Berg, T. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13, 1235–1242. [CrossRef] [PubMed]

203. Xu, G.; Zhu, L.; Wang, Y.; Shi, Y.; Gong, A.; Wu, C. Stattic Enhances Radiosensitivity and Reduces Radio-Induced Migration and Invasion in HCC Cell Lines through an Apoptosis Pathway. Biomed Res. Int. 2017, 2017, 1832494. [CrossRef] [PubMed]

204. Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102, 4700–4705. [CrossRef]

205. Miyoshi, K.; Takaishi, M.; Nakajima, K.; Ikeda, M.; Kanda, T.; Tarutani, M.; Iiyama, T.; Asao, N.; DiGiovanni, J.; Sano, S. Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor. J. Investig. Dermatol. 2011, 131, 108–117. [CrossRef] [PubMed]

206. Park, J.S.; Kwok, S.K.; Lim, M.A.; Kim, E.K.; Ryu, J.G.; Kim, S.M.; Oh, H.J.; Ju, J.H.; Park, S.H.; Kim, H.Y.; et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis. Arthritis Rheumatol. 2014, 66, 918–929. [CrossRef] [PubMed]

207. Mencalha, A.L.; Du Rocher, B.; Salles, D.; Binato, R.; Abdelhay, E. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother. Pharmacol. 2010, 65, 1039–1046. [CrossRef]

208. Fuh, B.; Sobo, M.; Cen, L.; Josiah, D.; Hutzen, B.; Cisek, K.; Bhasin, D.; Regan, N.; Lin, L.; Chan, C.; et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer 2009, 100, 106–112. [CrossRef]

209. Lin, L.; Hutzen, B.; Li, P.K.; Ball, S.; Zuo, M.; DeAngelis, S.; Fouest, E.; Sobo, M.; Friedman, L.; Bhasin, D.; et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010, 12, 39–50. [CrossRef]

210. Zhao, C.; Wang, W.; Yu, W.; Jou, D.; Wang, Y.; Ma, H.; Xiao, H.; Qin, H.; Zhang, C.; Lu, J.; et al. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget 2016, 7, 12971–12976. [CrossRef]

211. Siddiquée, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R.; McLaughlin, M.M.; Lawrence, N.J.; et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA 2007, 104, 7391–7396. [CrossRef] [PubMed]

212. Ball, D.P.; Lewis, A.M.; Williams, D.; Reseta, D.; Wilson, D.J.; Gunning, P.T. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent. Oncotarget 2016, 7, 20669–20679. [CrossRef] [PubMed]

213. Zhang, X.; Sun, Y.; Pried Edu, R.; Yang, H.; Urlam, M.K.; Lawrence, H.R.; Guida, W.C.; Lawrence, N.J.; Sebti, S.M. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013, 73, 1922–1933. [CrossRef] [PubMed]

214. Fletcher, S.; Singh, J.; Zhang, X.; Yue, P.; Page, B.D.; Sharma, S.; Shahani, V.M.; Zhao, W.; Schimmer, A.D.; Turkson, J.; et al. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities. Chembiochem 2009, 10, 1959–1964. [CrossRef]
215. Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P.T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. *Biochem. Pharmacol.* 2010, 79, 1398–1409. [CrossRef]

216. Zhang, X.; Yue, P.; Page, B.D.; Li, T.; Zhao, W.; Namenja, A.T.; Paladino, D.; Zhao, J.; Chen, Y.; Gunning, P.T.; et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. *Proc. Natl. Acad. Sci. USA* 2012, 109, 9623–9628. [CrossRef]

217. Haftchenary, S.; Luchman, H.A.; Jouk, A.O.; Veloso, A.J.; Page, B.D.; Cheng, X.R.; Dawson, S.S.; Grinshtein, N.; Shahani, V.M.; Kerman, K.; et al. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. *ACS Med. Chem. Lett.* 2013, 4, 1102–1107. [CrossRef]

218. Hayakawa, F.; Sugimoto, K.; Harada, Y.; Hashimoto, N.; Oh, N.; Kurahashi, S.; Naoe, T. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinas. *Blood Cancer J.* 2013, 3, e166. [CrossRef]

219. Kim, M.J.; Nam, H.J.; Kim, H.P.; Han, S.W.; Im, S.A.; Kim, T.Y.; Oh, D.Y.; Bang, Y.J. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. *Cancer Lett.* 2013, 335, 145–152. [CrossRef]

220. Wong, A.L.; Soo, R.A.; Tan, D.S.; Lee, S.C.; Lim, J.S.; Marban, P.C.; Kong, L.R.; Lee, Y.J.; Wang, L.Z.; Thuya, W.L.; et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. *Ann. Oncol.* 2015, 26, 998–1005. [CrossRef]

221. Kim, M.J.; Nam, H.J.; Kim, H.P.; Han, S.W.; Im, S.A.; Kim, T.Y.; Oh, D.Y.; Bang, Y.J. OPB-31121, a novel signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. *Cancer Sci.* 2015, 106, 896–901. [CrossRef] [PubMed]

222. Brambilla, L.; Genini, D.; Laurini, E.; Merulla, J.; Perez, L.; Ferrmeglia, M.; Carbone, G.M.; Pricl, S.; Catapano, C.V. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3). *Mol. Oncol.* 2015, 9, 1194–1206. [CrossRef] [PubMed]

223. Genini, D.; Brambilla, L.; Laurini, E.; Merulla, J.; Civenni, G.; Pandit, S.; D’Antuono, R.; Perez, L.; Levy, D.E.; Pricl, S.; et al. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolite synthetic lethality in cancer cells. *Proc. Natl. Acad. Sci. USA* 2017, 114, E4924–E4933. [CrossRef]

224. Orlova, A.; Wagner, C.; de Araujo, E.D.; Blajszczak, D.; Neubauer, H.A.; Herling, M.; Gunning, P.T.; Keseru, G.M.; Moriggl, R. Direct Targeting Options for STAT3 and STAT5 in Cancer. *Cancers* 2019, 11, 1930. [CrossRef] [PubMed]

225. Oh, D.Y.; Lee, S.H.; Han, S.W.; Kim, M.J.; Kim, T.Y.; Heo, D.S.; Yuasa, M.; Yanagihara, Y.; Bang, Y.J. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. *Cancer Res. Treat.* 2015, 47, 607–617. [CrossRef] [PubMed]

226. Bendell, J.C.; Hong, D.S.; Burris, H.A., 3rd; Naing, A.; Jones, S.F.; Falchook, G.; Bristrom, P.; Elekes, A.; Rock, E.P.; Kurzrock, R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. *Cancer Chemother. Pharmacol.* 2014, 607–615. [CrossRef] [PubMed]

227. Verdura, S.; Cuyas, E.; Llorach-Pares, L.; Perez-Sanchez, A.; Micol, V.; Nonell-Canals, A.; Joven, J.; Valiente, M.; Sanchez-Martinez, M.; Bosch-Barrera, J.; et al. Silibinin is a direct inhibitor of STAT3. *Food Chem. Toxicol.* 2018, 116, 161–172. [CrossRef]

228. Mertens, C.; Haripal, B.; Klinge, S.; Darnell, J.E. Mutations in the linker domain a impact phospho-STAT3 function and suggest targets for interrupting STAT3 activity. *Proc. Natl. Acad. Sci. USA* 2015, 112, 14811–14816. [CrossRef]

229. Kraskouskaya, D.; Duodu, E.; Arpin, C.C.; Gunning, P.T. Progress towards the development of SH2 domain inhibitors. *Chem. Soc. Rev.* 2013, 42, 3337–3370. [CrossRef]

230. Huang, M.; Song, K.; Liu, X.; Lu, S.; Shen, Q.; Wang, R.; Gao, J.; Hong, Y.; Li, Q.; Ni, D.; et al. AlloFinder: A strategy for allosteric modulator discovery and allosterome analyses. *Nucleic Acids Res.* 2018, 46, W451–W458. [CrossRef]

231. De la Iglesia, N.; Konepka, G.; Lim, K.L.; Nutt, C.L.; Bromberg, J.F.; Frank, D.A.; Mischel, P.S.; Louis, D.N.; Bonni, A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. *J. Neurosci.* 2008, 28, 5870–5878. [CrossRef] [PubMed]
232. De la Iglesia, N.; Konopka, G.; Puram, S.V.; Chan, J.A.; Bachoo, R.M.; You, M.J.; Levy, D.E.; Depinho, R.A.; Bonni, A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. *Genes Dev.* 2008, 22, 449–462. [CrossRef] [PubMed]

233. Schneller, D.; Machat, G.; Sousek, A.; Proell, V.; van Zijl, F.; Zulehner, G.; Huber, H.; Mair, M.; Muellner, M.K.; Nijman, S.M.; et al. p19(ARF)/p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. *Hepatology* 2011, 54, 164–172. [CrossRef] [PubMed]